



A Multimodal Strategic Approach to Integrative Oncology

Jesse A. Stoff ^{a*#}

^a *Integrative Medicine of New York, 520 Franklin Ave Suite 230 Garden City, NY-11530, USA.*

Author's contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

Article Information

Editor(s):

(1) Dr. Wagner Loyola, Brazilian Agricultural Research Corporation, Concordia.

Reviewers:

(1) Yue Jia, USA.

(2) Bhalchandra Mirlekar, University of North Carolina at Chapel Hill, USA.

Complete Peer review History, details of the editor(s), Reviewers and additional Reviewers are available here:

<https://www.sdiarticle5.com/review-history/77967>

Received 10 October 2021

Accepted 13 December 2021

Published 15 January 2022

Review Article

ABSTRACT

The term “integrative oncology” can mean particular things to different audiences. For the purposes of this article, I intend it to mean the simultaneous use of multiple anti-cancer strategies that can have a synergistic effect against the tumor, its microenvironment, and its propensity to metastasize. Thereby, having a maximum impact against the cancer with a minimum of side effects for the patient to endure. As noted in the references, this paper briefly describes the five prevailing evidence-based systematic approaches in use today. Each of these approaches has varying degrees of effectiveness which, in my experience, when clinically integrated, produces exponentially better efficacy, hence shifting progression-free survival into the possibility of increased overall survival and a durable remission. This paper is an attempt to offer some perspective of how to apply these disparate methodologies so that they may be more effectively integrated, resulting in consistently better clinical responses.

Keywords: Integrative oncology; oncology; multimodal strategic; cancer.

1. INTRODUCTION

Cancer, as a disease of our time, has been described as a “wound that does not heal” [1]

because it has a multitude of biochemical dysfunctions at its core. However, in order for these genetically and phenotypically abnormal cells to survive and thrive, the watchdog of the

[#]*Clinical Immunologist;*

^{*}*Corresponding author: E-mail: drstoff@imofny.org, jessestoff@gmail.com*

body, the immune system, must itself be suffering from a number of serious areas of structural and functional damage. From a perspective of ten thousand feet, there are two basic characteristics of cancer: genetic instability and the propensity to metastasize. From those two basic observational characteristics, the hallmarks of cancer were derived by Drs. Hanahan and Weinberg in 2000 as follows:

Self-sufficiency in growth signals. Insensitivity to antigrowth signals. Evading apoptosis, Limitless replicative potential, Sustained angiogenesis, Tissue invasion and metastasis.

And then the following were added in 2011:

Deregulating cellular energetics, Avoiding immune destruction, Genome instability and mutation, Tumor-promoting inflammation [2,3].

Based upon the characteristics of the cancer, there are five common office-based/out-patient strategies that we can employ. Each of these strategies is made up of a number of tactics based upon the unique expressed characteristics of the target cancer and the physiological individuality of the patient. Those five strategies are first, to balance and normalize the metabolism of the patient while inhibiting the physiology of the cancer. Second, to identify and seek to repair areas of damage within the structure and function of the immune system. Third, to identify actionable genetic and protein mutations that are driving the cancer and address them. Forth, to employ agents that can inhibit, suppress, or destroy the root of the problem, the cancer stem cells. And fifth, to directly attack the cancer with cytotoxic (chemotherapeutic) agents and radiation therapy. Utilizing agents that can decisively accomplish one of these strategies or that can engage and strike two or more of these objectives with less toxicity can lead to greater quality and quantity of life for our patients.

2. METABOLIC APPROACH

2.1 Biochemical Support of the Patient Milieu

Metabolic targeting is the first anti-cancer strategy because it lays the foundation for the improved response for all of the other strategies that follow. In 1498, Albrecht Durer created the famous woodcut entitled "The Four Horsemen, from the Apocalypse" which, in a sense,

foreshadowed the epidemic of severe and chronic diseases that we now face. From a metabolic, thousand-foot perspective, there are four major processes that are common pathways for the initiation and promotion of cancer. Each of which should be assessed for every patient: Glycation; which can be easily measured with blood sugar, hemoglobin A1C, and GlycoMark; Inflammation; for which there are a myriad of markers including ESR, CRP, plasma viscosity, adiponectin, monocyte chemoattractant protein 1 (MCP-1), CD40 ligand and lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), and ferritin to name but a few; Methylation; which can be watched with homocysteine levels; and finally, we come to Oxidation; which is largely reflected in levels of lipid peroxides and oxidized LDL. Current research demonstrates that cancer is largely a metabolic disease involving disturbances in energy production (deregulating cellular energetics) through a shift from respiration to fermentation, but this is not the only aberrant energy pathway that cancer cells can utilize. The genomic instability observed in tumor cells, leading to the other recognized hallmarks of cancer listed above, is now considered downstream epiphenomena of the initial disturbance of cellular energy metabolism which is often caused by a toxin [4]. The disturbances in tumor cell energy metabolism can be linked to demonstrated abnormalities in the structure and function of and within the mitochondria [5-7]. Extrapolating upon this research we come to several conclusions for therapeutic intervention.

Glycation starts with diet. Diet has been recognized and is now accepted by mainstream medicine as a viable strategy for minimizing the risk of getting cancer [8-10]. Furthermore, "a higher frequency of organic food consumption was associated with a reduced risk of cancer" [11]. A proper diet can address issues of nutritional deficiency and some toxin exposure while supplying necessary anti-oxidants and helping to manage glycation (while hopefully being delicious). When we apply a dietary strategy to someone with cancer, while recognizing the dysregulated metabolic mitochondrial foundation of the tumors, we come to a low carbohydrate/ketogenic diet. Because cancer is biochemically dependant upon sugar to maintain its fermentation metabolism, depriving it as much as possible, of sugar will further destabilize the cancer cells making it easier to trigger apoptosis, with the addition of other therapeutic agents [12,13]. One of those therapeutic agents is Metformin. In addition to

lowering blood sugar levels and thus minimizing the fuel source for cancer cells, Metformin interferes directly with cell proliferation and supports apoptosis in a non-insulin-mediated manner. Accumulated research and clinical evidence suggest that Metformin exerts its positive effect on the clinical course of neoplastic diseases, primarily through the stimulation of 5' AMP-activated protein kinase (AMPK) in association with the upstream liver kinase B1 (LKB1) [14,15]. AMPK is a key cellular energy sensor, activation of which by Metformin leads to suppression of energy-consuming processes such as gluconeogenesis [16,17]. In carcinoma cells, the stimulation of AMPK, mediated by Metformin, resulted in the inhibition of the mTOR/ribosomal S6 kinase pathway and thus inhibition of the pathological cell cycle progression, cell growth, and angiogenesis [18,19]. This is a particularly important effect when there is a mutation of phosphatase and tensin homolog (PTEN) which would normally downregulate this pathway [20].

Inflammation is another metabolic pathway that drives cancer, therefore, anti-inflammatory strategies are of critical importance against cancer [21]. Inflammation results from or is triggered by virtually every disease known to man and has cellular pathways, plasma cascades, and acute and chronic markers. Some of the markers associated with cancer include CRP, IL-6, IL-8, and TNF-alpha. Inflammation can stimulate cancer stem cells as well as more mature tumor cells, triggering disease progression. Inflammation is a defense mechanism that serves to protect us from acute inflammatory illnesses (infections) and injuries that historically, from an evolutionary point of view, were the main causes of death. Inflammatory proteins activate the Th2 pathway which generates more inflammation. In doing so, in an apparent effort to focus and conserve resources, when the Th2 pathway becomes chronically stimulated by infection, vaccinations, nutritional deficiency, sugar, alcohol, trauma, stress, or toxins, it suppresses the Th1 pathway which is a critical pathway of the immune system, needed to protect us from, and fight cancer. Cimetidine can help to restore the Th1/Th2 balance and overcome pro-inflammatory Th2 dominance [22]. Activation of the Th1 pathway and its downstream effector cells results in the production of Reactive Oxygen Species (ROS). Which are inflammatory molecules that act locally to kill cancer cells, so we don't want to negate all inflammatory responses [23].

An important enzyme for the inflammatory response is cyclooxygenase (COX), which is critical for the conversion of arachidonic acid to prostaglandins and other Eicosanoids. It exists as two isoforms: COX-1 and COX-2; COX-1 is constitutively expressed whereas COX-2 is a highly inducible gene that is activated by cytokines, growth factors, phorbol esters, oncogens, and chemical carcinogens. COX-2 plays a key role in carcinogenesis as has been demonstrated in numerous cancer cell types. Multiple pathways have been proposed to explain how increased COX-2 expression might contribute to carcinogenesis including elevated BCL-2 protein levels and inhibition of apoptosis, increased angiogenesis, and enhanced metastatic activity. Suppressing COX-2 activity, or at least not stimulating it, which many chemotherapeutic agents do, is an important part of any anticancer strategy. Many agents have been identified that suppress COX-2 activity, which can be assayed in vitro and is reflected clinically in decreased levels of CRP, interleukin-6 (IL-6), P-selectin, matrix metalloproteinase-9 (MMP-9), tumor necrosis factor (TNF- α), and other inflammatory markers. Some of the anti-inflammatory agents that are helpful against cancer include Celecoxib, fish oil, (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), white willow tree, curcumin, green tea, pycnogenol, Boswellia, resveratrol, cats claw, and capsaicin to name just a few of the most common medicaments[24-49].

Methylation seems to still be incompletely understood when it comes to cancer. On the one hand, people with the fairly common methylenetetrahydrofolate reductase (MTHFR) mutation are at a higher risk of getting certain (and maybe all) cancers [50]. This makes sense because that gene affects some of the liver detox pathways and when it isn't working well it can lead to known increased risks for cardiovascular heart disease, leukemia, breast cancer, colon cancer, and many other illnesses [51]. The mutation can be tested for and some of its effects monitored with homocysteine blood levels. Many of the negative effects can be bypassed with methylated B vitamins. On the other hand, gene expression can be significantly modulated by alterations in DNA methylation patterns. Methylation within the promoter regions of tumor suppressor genes causes their silencing, and methylation within the gene itself can induce mutational events. These mechanisms may play a fundamental role in precipitating the development of a large and diverse number of

human cancers[52]. It is important to monitor homocysteine and B vitamin levels while treating people with cancer, because overshooting your mark may make some cancers worse [53]. When a woman is pregnant we give prenatal vitamins which are largely B vitamins to stimulate the cell growth of the fetus, and when you're fighting cancer you don't want to do that. However, it is important to note that, B vitamin deficiencies will inhibit many immune functions that are desperately needed for the fight [54]. Nothing about fighting cancer is easy, getting biochemical moieties to and maintaining them within the normal range is a safe bet, from a metabolic perspective.

Oxidation, like the rest of metabolic activity, is also a bit of a double-edged sword when it comes to cancer. Oxidative stress is caused by many things including; obesity, high fat diet, sugar, the chemicals in processed foods, radiation, smoking, alcohol, Covid-19, environmental pollution and chemicals, etc., etc., etc..(i.e. life) [55]. Damage from oxidative stress occurs when the cells and tissues are unable to keep up with harm done by the free radicals that are generated from the above, and other causes. A free radical is an atom, molecule, or ion that has an unpaired valence electron that can bind to, and damage, DNA and messenger molecules but is normally kept in check by the body's store of anti-oxidants. This damage is carcinogenic. Anti-oxidants can mitigate oxidative stress and are found in vegetables such as broccoli, spinach, carrots, cabbage, and vitamins C, E, D, A, etc., etc., etc... Uncontrolled oxidative stress can activate a variety of transcription factors including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), activator protein 1 (AP-1), tumor protein 53 (p53), Hypoxia-inducible factor-1α (HIF-1α), Peroxisome proliferator- activated receptor gamma (PPAR-γ), β-catenin/Wnt, and nuclear factor erythroid 2-related factor 2 (Nrf2). Activation of these transcription factors can lead to the expression of over 500 different genes, including those for growth factors, inflammatory cytokines, chemokines, and cell cycle regulatory molecules. Activation of these molecules by oxidative stress stimulates inflammatory pathways leading to the transformation of a normal cell to a tumor cell, increases tumor cell survival, proliferation, chemoresistance, radioresistance, invasion, angiogenesis and supports cancer stem cell survival [56]. On the other side of the sword, the production of oxidative reactive oxygen species (ROS) is

required for the function of another major effector of the innate immune system, Natural Killer (NK) cells—hydroxyl radical production is responsible for NK cells-mediated cytotoxicity, by promoting the secretion of cytotoxic factors from NK cells granules [57-62]. ROS can promote carcinogenesis by inducing genetic mutations, activating oncogenes, and raising oxidative stress, which can stimulate cell proliferation, survival, and reduce apoptosis. Over the past few decades, natural compounds have attracted attention as potential cancer therapies because of their ability to maintain cellular redox homeostasis with minimal toxicity. Research and clinical studies show that bioactive dietary polyphenols exert antitumor effects by inducing ROS-mediated cytotoxicity in cancer cells. These bioactive compounds also regulate cell proliferation, survival, and apoptotic and antiapoptotic signaling pathways [63]. Amongst many other examples, this is demonstrated in the ability of Aronia melanocarpa to increase the expression and activity of p53 and p73 that leads to the down-regulation of the expression of cyclin B1, which contributes to the cell cycle arrest of cancer cells [64-66].

Some commonly used anti-cancer agents include:

Glycation
Metformin [67,68]
Berberine [69,70]
Azadirachta indica (neem) [71,72]
Inflammation
Celebrex [73]
Curcumin [74,75]
Grape Seed Extract [76,77]
Cimetidine [78]
Viscum [79]
Methylation
Decitabine [80]
EGCG [81]
Oxidation
DMSO [82]
Raloxifene [83]
Vitamin C and MANY other vitamins and minerals [84]

2.2 Biochemical Targets of the Tumor: The Micro-environment

A closer look at the cancer itself demonstrates that by corrupting and recruiting non-malignant cells in the area, the tumor has created its own biochemical tumor microenvironment (TME)

suitable for its self-protection and propagation [85]. Many different cell types, besides the cancer, can be found in the TME including; adipocytes, fibroblasts, dendritic cells, lymphocytic endothelial cells, myeloid-derived suppressor cells, pericytes, tumor-associated macrophages, tumor-associated neutrophils, and vascular endothelial cells, to name but a few [86]. Other cells to be found in TME include T-cells, NK cells, NKT cells, and some B-cells that are there to fight the good fight. Dendritic cells and macrophages found just outside of the TME are also engaged in the battle against the cancer, but if consumed by the tumor, seem to become corrupted and aid in its survival [87]. The dynamic interactions of the cancer cells with the stromal cells (cellular part) and extracellular matrix (ECM) components (non-cellular structures) are essential for stimulating the multiple cell lines of the cancer, as well as its clonal evolution and propensity to develop multidrug resistance, resulting in cancer cell progression and metastasis [88]. The ECM holds cells, tissues, and organs together and maintains the three-dimensional structure of the body. For a cancer cell to metastasize from the primary tumor to other organs, it must locally degrade the ECM components that are the physical barriers to cell motility. Cancer cells build, shape, and recruit support for their TME through the release of many different types of molecules including; matrix remodeling enzymes, mediators of inflammation (which can stimulate the activity of the matrix metalloproteinases), cytokines, cell-free DNA (cfDNA, which we can now test for [89]) chemokines, growth factors, exosomes, and can facilitate horizontal gene transfer [90]. The reciprocal and self-supporting cell-cell/ECM interaction forces the expression of new phenotypes of non-cancer cells that promotes the development and invasion of the cancer at large [91].

Trying to bring order back to such a maelstrom is the focus of a great deal of research at this time as it is an important piece of a durable remission. Targeting the TME has proven to be no easy feat and has been based upon trying to undermine the major components of it. Starting with the milieu itself, it has long been noted that the TME is more acidic than normal tissue in the local area, while the intracellular Ph is often more alkaline [92]. However, just trying to inject the TME with sodium bicarbonate does not seem to be a reliably effective treatment because the active biological processes that created the abnormal gradient, to begin with, will rebound

and increase its level of activity to re-establish its supportive environment. Combining sodium bicarb with cytotoxic agents seems to offer a better strategy [93,94]. Changing the electrochemical gradient of the TME, and thus the Ph, with an electrical current has also shown to be effective in some cases [95-97].

Another strategy that targets the TME is to inhibit the matrix metalloproteinases (MMPs) that degrade the extracellular matrix (ECM) components that then allows for local metastasis. Research has identified many substances that can inhibit these MMP's. Resveratrol, a polyphenol present in various plants, food products, red wine, and grapes, has been demonstrated to suppress MMP-2 and MMP-9 [98]. Additionally, resveratrol can inhibit the expression of Vascular endothelial growth factor (VEGF) and act as an anti-inflammatory agent [99]. Agents derived from marine sources have also been found to inhibit MMP's including various plant and animal sources of saccharoids, flavonoids, polyphenols, and fatty acids but thus far, few have been shown to be reliably clinically effective [100]. One agent that did make it into clinical trials was AE-941/Neovastat. According to the National Cancer Institute, "shark cartilage extract, AE-941 competitively inhibits the binding of pro-angiogenic vascular endothelial growth factor (VEGF) to its cell receptor, thereby inhibiting endothelial cell proliferation". This agent also inhibits matrix metalloproteinases (MMPs), but at this time, there are no clinical studies involving its use [101]. Chlorella, a protein extract from algae has also been shown to have MMP's inhibitory properties [102]. Tissue inhibitors of metalloproteinases (TIMP's) naturally impede the activity of the MMP's and its the imbalance between the activation and inhibition of them that is largely responsible for the progression of a tumor's growth [103]. Other polyphenols that can inhibit the MMP's are quercetin, epigallocatechin gallate, and curcumin. They act as dynamic antioxidants, and are able to interact with cell-signaling pathways, modulating gene expression in three different ways: i) influencing the activity of transcription factors, ii) epigenetically, modulating microRNAs, and iii) having an anti-inflammatory effect, all of these actions serve to down-regulate MMP activity [104]. Combining polyphenols with amino acids that are used in the production of the ECM along with vitamin C which, too, is critical for ECM support, has been shown to be an effective strategy for slowing the progression of tumors. Their combined anti-cancer effects include

inhibition of: metastasis, tumor cell growth, matrix metalloproteinase secretion and activity, local invasion, angiogenesis, as well as induction of apoptosis of the cancer cells [105-108]. This combination has been effective both in vitro and in vivo against many different cancers and cancer cell lines including ovarian, melanoma, squamous cell, and others in a dose-dependant curve [109]. A chief problem for the use of polyphenolic compounds against cancer is their low bioavailability [110]. Different types of formulations have been designed to address this issue, nanonization being one of the most notable approaches among them. Variations of nanoformulations are designed to be effectively transported through the relevant biological barriers to the targeted organs, tissues, and cells. Research on natural polyphenols as bioactive agents include: resveratrol, curcumin, quercetin, epigallocatechin-3-gallate, chrysin, baicalein, luteolin, honokiol, silibinin, and coumarin derivatives, which have shown efficacy in a dose-dependent manner and may result in better treatments of cancer [111].

The tumor microenvironment, created by the cancer, further supports its dysfunctional growth and ability to metastasize through epigenetic changes. Epigenetic changes are heritable but, unlike genetic nucleotide modification, are reversible and therefore targetable as part of an oncolytic therapy. A variety of epigenetic mechanisms have been identified that can induce and/or support a cancer, such as: silencing of tumor suppressor genes, activation of oncogenes by altered cytosine phosphorus guanine (CpG) island methylation patterns, histone modifications, and dysregulation of DNA binding proteins. A quick search in <https://www.ncbi.nlm.nih.gov/pmc> for "epigenetic toxins and human cancers" will yield thousands of articles about substances both natural and synthetic that can create such changes [112]. Not only are the epigenetic changes potential targets for treatment, but their inducers are as well [113,114]. The TME creates and supports epigenetic biochemical reactions that dynamically regulate DNA expression. Nucleotide methylation and histone modification induce the dysregulation of genes related to proliferation, apoptosis, and metastasis [115]. DNA methylation is strongly associated with the repression of transcription of tumor suppressor genes through adding a methyl group by DNA methyltransferases (DNMTs) [116]. Other reactions by histone deacetylases (HDACs) contribute to transcriptional repression by

removing the acetyl group at lysine residues leading to tumorigenesis, as a result of the research, both biochemical pathways have become the focus of intense research to develop DNMT and HDAC inhibitors [117]. Histone acetyltransferases (HAT), erasers (histone demethylases (HDM) and histone methylases (HMT) have also become epigenetic targets of research [118]. Some drugs are currently available and used for their epigenetic effects such as Decitabine, which can prevent DNA re-methylation and re-activate silenced suppressor genes [119]. Azacitidine is considered a global DNMT inhibitor and upon treatment of breast cancer cells, DNA re-methylation was inhibited for 23 out of 26 tested hypermethylated genes, allowing 5 tumor suppressor genes to be re-expressed [120]. The problem with these and the many other drugs, thus far developed for their epigenetic effects, are the unintended consequences (side effects) on normal, healthy cells elsewhere in the body. Reducing and pulsing the doses given has helped somewhat to reduce the side effects while maintaining efficacy [121].

The tactics for targeting the TME have a certain amount of overlap with those that seek the destruction of the cancer stem cells because they are the major architects of their immediate environment. However, the chief goal of an anti-metabolic cancer therapy is to disrupt the energy production pathways that support the cancer cells. For example, ENOX2 is a gene located on the long arm of the X chromosome and encodes for the Ecto-NOX protein. It is a member of the NOX family of NADPH oxidases which are important for energy production and the growth of the cell. Tumor-associated NADH oxidase (tNOX), has been identified as a target for low-dose cell killing (apoptosis) of cancer cells by green tea catechins and Capsicum vanilloid combinations [122-125]. This protein is uniquely associated with all forms of cancer and is absent from normal cells and tissues. Another anti-cancer metabolic strategy is to use the combination of two nutraceuticals: lipoic acid and calcium hydroxycitrate, which target two cancer energy enzymes ATP citrate lyase and pyruvate dehydrogenase kinase. Experimentally, this treatment was as efficient as chemotherapy in the mouse cancer models that were tested [126,127]. Clinically, in combination with low-dose naltrexone, this anti-metabolic tactic has also been effective even against advanced chemo-resistant carcinomas [128, 129].

2.3 Genetic Molecular Targeting

Targeting the abnormal genetics of cancer is the second anti-cancer strategy. Before we even begin to specifically target aberrant genetics, there are therapies that can be instituted for generally stabilizing genes which buys time for more definitive testing that allows for precise targeting of the cancer genome. Each of these agents has a multitude of beneficial effects, but chief among them is their ability to stabilize aberrant genetics, creating the time and opportunity for an integrative anticancer strategy. During the course of oncogenesis and tumor progression, cancer cells constitutively upregulate signaling pathways relevant to cell proliferation as a result of any number of genetic mutations. It is that genetic instability that leads to cancer cells acting as cancer in the first place, and it is those unstable mutations that account for the multiple cell lines that compose every tumor. Many agents have been identified that can aid in cell differentiation and reversion back to a phenotypically normal cell type [130]. Some of them are considered as follows.

First on our list of genetic stabilizers is dimethyl sulfoxide. Dimethyl sulfoxide (DMSO) is an organosulfur compound with polar, aprotic, and amphiphilic properties. It serves as a solvent for many polar and nonpolar molecules and continues to be one of the most used solvents (vehicle) in medical applications and scientific research. It also displays a diversity of antitumor activities[131]. Previous studies have demonstrated that DMSO can modulate AP-1 activity and lead to cell cycle arrest at the G1 phase [132]. The fibrinolytic system, more appropriately referred to as the plasminogen activator (PA) system, controls not only the intravascular fibrin deposition (with its effects on cardio-vascular disease) but also participates in a wide variety of other physiologic and pathologic processes. In cancer, the components of this system are involved in tumor growth, invasion, and metastasis through their effect on angiogenesis and cell migration, by way of its effects on the extracellular matrix of the tumor microenvironment. Plasminogen activator components are found in most tumors and their expression signifies not only their function but also carries a prognostic value. Their expression is in turn modulated by cytokines and growth factors, many of which are up-regulated in cancer and found throughout the TME. DMSO can inhibit the activity of PA's which helps to stabilize the TME and reduce the risk of

metastasis [133]. Furthermore, DMSO can cause the maturation/differentiation, of at least some cancers, into a benign, more normal cell type [134,135].

Vitamin D is next on our list of genetic stabilizers. In addition to enhancing DNA repair, vitamin D also induces growth arrest and apoptosis of tumor cells and their nonneoplastic progenitors. Cell-based studies show that the active metabolite 1,25 dihydroxyvitamin D is the biologically active form that works through the vitamin D receptor to regulate gene transcription. Vitamin D (D_3) is produced from 7-dehydrocholesterol when skin is directly exposed to UVB light which, in more northern locations, is largely filtered out by the atmosphere. Vitamin D is readily sourced from various foods including fish, eggs, caviar (for the gourmets among us), some mushrooms, beef liver, and cheese. Regardless of whether vitamin D comes from the skin or the diet, vitamin D_3 is transported through the blood by the vitamin D Binding Protein (DBP). Once delivered to the liver, vitamin D is hydroxylated on its side chain to form 25 hydroxyvitamin D ($25OH D$). This is a stable metabolite whose serum levels are commonly used to assess vitamin D status. As needed and if available, D_3 circulates to the kidneys which is the primary site where the active form of vitamin D, $1,25(OH)_2 D$, is produced through the genomic actions of $1\alpha,25(OH)_2$ via the vitamin D receptor (VDR), and its analogs inhibit cell cycle progression and tumor cell growth. Mechanisms of action range from preventing cell proliferation (through cell cycle arrest) in cancer cells to inducing apoptosis, or suppressing cell adhesion molecules and growth factors that promote cellular homing and metastasis. It also affords important antioxidant protection and serves as an immunomodulatory for both the innate and adaptive arms of the immune system [136-140].

Next comes indole-3-carbinol and its metabolite 3,3'-diindolylmethane (DIM). They target multiple aspects of cancer cell cycle regulation and survival including Akt-NF κ B signaling, caspase activation, and cyclin-dependent kinase activities. Furthermore, they stabilize estrogen metabolism, normalize estrogen receptor signaling, reduce endoplasmic reticulum stress, and limit BRCA gene expression. DNA hypermethylation is a common feature of cancer genetics. When methylation detox pathways start to fail, certain regions of the genome will accumulate too many methyl groups, such as at CpG promoter regions (segments of the DNA involved in DNA and RNA

transcription); this can lead to increased mutagenesis and eventual cancer development. Much research has demonstrated how DIM reduced methylation at 5 CpG promoter regions. For example, in split population studies, mice given Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) prostate cancer cells were also given DIM. The mice given the DIM showed a much lower incidence of cancer and metastasis than controls, as well as much higher expression of antioxidant/anticarcinogen protective enzymes NQO1 and NFR2 in prostate tissues [141-146].

Curcumin, a component of turmeric (*Curcuma longa*), is a low molecular weight molecule that has antiproliferative activity and inhibits tumor initiation and propagation through a variety of pathways. It accomplishes this through several epigenetic effects that result in genetic modulation that then changes the expression of several key proteins, some of which are the cysteine-aspartic acid proteases (caspases). Caspases are a family of enzymes that play an essential role in apoptosis, necrosis, and inflammation. Research demonstrates that curcumin activates caspases-3 and -8 but not caspase-9, indicating that the apoptosis induced in cancer cells occurs via a membrane-mediated mechanism. Membrane-bound enzymes play other important roles in the perpetuation of cancer cells such as the ECTO-NOX 2 system.

p53 (TP53) is a tumor suppressor gene and is responsible for protecting cells from tumorigenic alterations. Mutational inactivation of p53 is frequently observed in many cancers. Curcumin selectively increases p53 expression during the G2 phase of the cell cycle of carcinoma cells and releases cytochromes from the mitochondria, which is an essential requirement for then inducing p53-dependent apoptosis in the cancer cell.

Another protein affected by curcumin is Akt (protein kinase B), a serine/threonine kinase. It is a critical enzyme in signal transduction pathways involved in cell proliferation, apoptosis, and angiogenesis. Curcumin inhibited the phosphorylation of Akt in a dose-dependent manner leading to another pathway of apoptosis.

Curcumin also induces the upregulation of carcinogen-detoxifying enzymes, such as glutathione S-transferases, which have antioxidation effects and suppresses cyclooxygenase that in turn lead to the reduction of the level of inflammation and the stimulation of

cancer stem cells. Real-time animal model studies have demonstrated that curcumin also decreased the expression of DNA damage response genes, including serine/threonine kinase (ATM), ataxia telangiectasia and Rad3-related protein (ATR), breast cancer 1 (BRCA1), 14-3-3 σ , DNA-dependent protein kinase (DNA-PK), and O6-methylguanine-DNA methyltransferase (MGMT); thus, the reduction of a DNA damage response is but a part of the reason for curcumin-induced growth inhibition of cancer cells [147-149].

Sulforaphane (SFN) is an isothiocyanate found in cruciferous vegetables such as broccoli, brussels sprouts, cauliflower, and cabbage. Experimentally, in cell cultures and animal models, SFN was shown to be a highly effective chemoprotective against carcinogen-induced, and genetic animal cancer models, as well as in xenograft transplant models of cancer. The early research focused on the detoxification ability of SFN to induce phase 2 enzyme pathways. Later studies showed that SFN could cause cancer cells to enter G2/M phase arrest and result in apoptotic cell death, with the latter being evidenced by caspase-mediated cleavage of poly(ADP-ribose) polymerase and increased release of histone-associated DNA fragments from the tumor downstream. Furthermore, it leads to the transcriptional activation of genes including tumor suppressor genes. The effect on cancer genetics is profound and therapeutically beneficial [150-153].

Fish oil rounds out our list of top genetic stabilizing supplements. One of many changes that occur to the cancer cell's biochemistry and genetics is in the production, metabolism, and expression of microRNAs (miRNAs). First discovered in the early 1990s, their importance as a distinct class of biological regulators was not appreciated for another decade. MicroRNAs (miRNAs) are short molecules, just 21–25 nucleotides long, but can have powerful effects on gene expression. More than 2000 miRNAs have been identified including many specific miRNAs that have been found to be associated with cancer and the risk of metastasis. The identification of circulating miRNA specific to metastatic cancer presents a unique opportunity for early disease identification and for monitoring disease burden as a circulating biomarker. For example, abnormal activation of some miRNAs found in the blood, let-151a, miR-21, miR-155, miR-145, miR-18a, and miR-16, as well as tissue-specific miRNAs, miR-182, miR-145, miR-

21, miR-155/154, miR-203, miR-213, and miR-7, are often found in patients affected by breast cancer. Furthermore, there is a growing body of evidence on the value of miRNAs associated with the development of drug resistance, suggesting their values, once targeted, as a potential approach to overcoming chemoresistance. miRNAs that are absorbed into our bloodstream from genetically modified organism (GMO) foods are currently being studied for their oncogenic potential, as they are normally foreign to human biology. Fish oil can modulate the expression of the miRNAs which can significantly reduce the risk of metastasis while having many other anticancer effects [154-159].

The science of genetics studies the genes that make up our chromosomes, which lead to inherited characteristics; think Gregor Mendel and his peas. Genomics is the study of large groups of genes or even the entire genome, looking for mutations, fusions, deletions, loss of heterozygosity, etc. variations and alterations that lead to the expression of cancer. Aberrations of the genome lead to the transcription of the faulty gene into a messenger RNA (mRNA) molecule, that leaves the cell nucleus and enters the cytoplasm, where it directs the synthesis of the protein for which it encodes. Abnormal genes lead to abnormal proteins. The study of proteins is called proteomics; it's primarily the functional proteins, which includes enzyme activities, as well as protein/protein interactions (such as immune receptor sites) and post-translational modifications of the proteins that are of the most interest because they are the most antigenic and hence the most targetable/treatable. The sciences of genomics and proteomics have opened the door to what is being referred to as "precision medicine" [160]. Precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person". This personalized approach allows clinicians to predict more accurately which treatment is more likely to work for which person [161]. This is in contrast to a one-size-fits-all approach, in which cancer treatment strategies are developed for the average person based upon group clinical trials (cohorts), with little consideration for the differences between individuals.

Precision medicine works by profiling live or preserved cells for biomarkers that indicate an abnormal process, gene or protein is present that

is carcinogenic and/or cancer-promoting [162]. Cancer inhibiting genes that have been abnormally silenced are also tested for. Cutting edge technologies that can detect these clinically useful aberrations include: Next-Generation Sequencing (which allows for whole-exome DNA sequencing and whole transcriptome RNA sequencing), DNA Sequencing (sequence analysis reliably detects DNA mutations, copy number variations, and gene fusions across the entire exome), RNA Sequencing (is done to detect clinically relevant aberrations, in particular, gene-fusion events and splice variants), Immunohistochemistry biomarkers, in situ hybridization (to detect amplification and fusion events), and methylation analysis. When evaluated as a group, disease-specific lab test panels are developed which can then zero in on the aberrations for any individual patient to improve the therapeutic response [163-165].

Based upon the biomarkers found, clinically beneficial therapies may be employed including the use of; hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules [166,167]. Some of the commonly used small molecules include the "nibs" (tyrosine-kinase and serine/threonine kinase inhibitors) and the "mabs" (monoclonal antibodies). Monoclonal antibodies have been developed to attack growth receptors of the cancer cells, growth factors for new blood vessels that feed the tumor, and targets on cells of the immune system to dis-inhibit their activity [168]. Natural substances too can be used to target specific aberrations; a few, of many, examples [169,170]:

p53, p73	Aronia melanocarpa [171,172]
VEGF	Omega-3 Fatty Acids [173]
JAK/STAT-3	Astaxanthin [174,175]
PI3K/AKT	Viscum alb [176]
KDR	Artemisinin [177]
MMP2, MMP9	Curcumin [178]
HER2-neu	Quercetin [179]
EGFR	Silymarin [180]
VE-cadherin	Camellia sinensis [181]
HIF-1 α	Ginseng [182]
NF- κ B	Liquorice [183]
BCL2	Scutellaria baicalensis[184]
KRAS	Coffee [185]
Mcl-1	Piperlongumine [186]

2.4 Immunotherapy

Immuno-therapy is the third anti-cancer strategy. Edward Jenner was a pioneering English physician and scientist who improved the procedure of smallpox inoculation to create the smallpox vaccine in 1796 [187,188]. In the scientific fashion, he purposely exposed people that he had vaccinated against smallpox to prove that the cowpox pus that he used did indeed confer protective resistance. Although others before him had used cowpox to provide protection from smallpox, he was the first to then demonstrate that it did in fact work and that the effect was reproducible in subsequent patients [189-191]. Although not understanding the intricacies of the immune system, because he applied the scientific method, as it existed in his time, he is referred to as the “Father of Immunology” [192].

Since Jenner’s time, immuno-therapy has evolved into an office-based strategy for which they write very thick books and, in the broadest terms possible, it is a treatment that uses the immune system, in some way, to identify, attack, and destroy the cancer. Using the immune system against cancer can be accomplished through active or passive pathways. As a quick overview, there are over one hundred and eighty-seven cell types identified within the immune system. It includes the lymphatic system along with the bone marrow, spleen, thymus, and, of course, lymph nodes. Cells known as CD4 T cells are the “apparent brains” of the immune system and they coordinate the central immune response to any serious health threat. Activated B cells become plasma cells and, in most instances, generate an antibody response against bacterial and viral invasion. Lymphokine activated killer cells and cytotoxic T cells respond to viruses and cancer. Suppressor T cells are used to downregulate the actions of the immune system after the threat has been eliminated through negative feedback. Macrophages are voracious amoeboid-like lymphocytes that eat foreign substances and send a message back to the rest of the immune system indicating what further immune response is necessary. Macrophages and their cousins, the dendritic cells, are involved in all aspects of the immune response by initially sending out the alarm that something is amiss. Natural Killer cells are preprogrammed at their birth to destroy virally infected cells, cancer cells, some bacteria, and parasites on contact without the need for further direction from the CD4 cells. Some mushroom extracts and the bioengineered

nutraceutical AiE10™ can increase the concentration and activity of natural killer cells.

The immune response cascade operates according to three directives. The first is to recognize that which is foreign and sound the alarm soon enough to thwart the invader. Molecules and cell surfaces that are identified as foreign are referred to as antigens and have the ability to elicit an immunogenic response. The second directive is to respond to the alarm with enough of a counterattack to effectively neutralize the invader quickly. The third directive is to remember what happened so that if the same situation were to arise again, an effective response could be generated faster. The length and efficacy of the immune response depends upon the “intactness” of the underlying biochemistry. The immune response cascade is the ultimate biological information processing and transfer vehicle designed to define, defend, and integrate oneself relative to the environment that surrounds us. When there is a miscommunication, disease ensues due to corruption, misdirection, or a lack of that informational flow.

Active immune therapies include, among other agents, IL-2, IFN-g, and IFN- α cytokines to stimulate the TH1 cells, pathways, and natural killer cells. Monoclonal antibodies, checkpoint inhibitors, that disinhibit an immune response are also an active immunotherapy that seems to be most effective when some support has been given to the immune system first. Other active therapies include creating primed dendritic cells (for example, Sipuleucel-T (Provenge)) and natural killer cells and then infusing them into the patient to “patch” holes and reconstitute an effective anticancer response.

Passive immunotherapies include the use of infused antibodies to bind to cancer cells. Then, when natural killer cells encounter antibody-coated cells, the latter’s Fc regions interact with their Fc receptors, releasing perforin and granzyme B to kill the tumor cell. Adoptive T cell therapy is another passive immunotherapy. Several ways of producing and obtaining tumor-targeted T cells have been developed. T cell Infiltrating Lymphocytes (TILs), specific to the tumor antigens, can be removed from a tumor sample with a core biopsy and then purified with a cell separator or filtered from the blood. Subsequent activation with cytokines and cell culturing is performed *ex vivo*, and then the results were reinfused into the patient. Activation

can take place through gene therapy or by exposing the T cells to tumor antigens in the presence of cytokines. TILs can also be stimulated in vivo with hypofractionated SBRT to induce an abscopal effect, which when achieved can have miraculous results. According to the National Cancer Institute, the abscopal effect “describes the shrinking or disappearance of tumors in parts of the body that were not the direct target of local therapy” [193]. It was first described in 1953, by a researcher named R. H. Mole who demonstrated that radiation could shrink a tumor on one side of a mouse and lead to the regression of an untreated tumor on the other side of the animal [194]. He coined the term “abscopal effect” from the Latin *ab* (position away from) and *scopus* (mark or target). Since the phenomena was first observed using radiation, it was assumed that that was the key to the response. A lot of research has been done on varying different parameters of the radiation in order to reliably reproduce the effect [195]. Tumor-infiltrating lymphocytes are seen as an important part of the “recipe” as they can signal and initiate a counter-tumor cascade and bode well prognostically [196]. Further research has demonstrated that cryotherapy, too, can trigger an abscopal response [197]. In my experience, it seems that any locally applied treatment that causes the sudden death of a large number of cancer cells, thus quickly releasing antigens, without suppressing normal systemic physiology (i.e. the immune system), can trigger a cascade of events that can lead to the death of tumors far removed from the point of the therapy. This includes; radio frequency ablation (RFA), hyperthermia, hi frequency ultrasound (HiFu), cryotherapy, and of course fractional dose radiation therapy [198-204].

Combining these “mildly” oncolytic therapies with checkpoint inhibitors has yielded better results [205,206]. The checkpoint inhibitors are helpful only to the point that the immune system is still basically structurally intact and functionally effective. When the principles of immune reconstitution are followed, the therapeutic response can be much more beneficial [207].

A “new”, state-of-the-art, passive immunotherapy is the use of chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors, or artificial T cell receptors) which are bioengineered cell receptors that combine a new specificity with an immune cell to target cancer cells. Essentially, what is done is that specific monoclonal antibody

fractions are grafted onto T cell receptors. The receptors are referred to as chimeric because they are a fusion of proteins and receptors from different immune sources. CAR-T cell therapy refers to an infusion of such specifically transformed cells for targeted cancer therapy. CAR-T cells destroy the cancer cells through several mechanisms such as having a direct cytotoxic effect and/or stimulating other cells of the immune system through the release of various cytokines and growth factors. Due to the CAR-T cells very narrow specificity, less prominent tumor cell lines can be missed allowing for a future recurrence [208-218].

Overall, immunotherapy is designed to correct, stimulate, direct, or reconstitute an effective anticancer response. Immune reconstitution is the evolving clinical science of restoring immune competence by correcting biochemical imbalances, augmenting cytokines, restoring cascade pathways, and/or implanting specific stem cells to bridge areas of damage. All severe or chronic diseases are known to have one or more significant defects in the immune system adversely affecting the immunological imperatives of recognition, response, and memory which, in the case of cancer, leads to anergy and tolerance. Testing for and breaking anergy is the first step in immune reconstitution [219]. Correcting anergy is of critical importance because it directly correlates to the stage of cancer: over 90% of patients with Stage 4 disease are found to be anergic [220]. The immune system cannot fight something that it doesn't know is there, and that's exactly what arises with anergy. Anergy manifests when there is a failure of signal transmission at ANY point in the immune response cascade. Before we can break anergy, and wake up the immune system, we must make sure that we are dealing with true anergy as opposed to another pathology.

Of historical interest, some years ago the Mérieux Company manufactured a skin test called the “Multitest Mérieux” or “CMI Multitest” system (Istituto Merieux Italia, Rome, Italy). It is used as a general test for the level of the cellular immune response. It is an intradermal test of skin reactivity (similar to allergy tests) in which a control (glycerol) is used with seven common antigens of bacterial or fungal origin (tetanus toxoid, tuberculin, diphtheria, streptococcus, candida, trichophyton, and proteus). In this test, reactions are categorized according to the number of antigens provoking a response, and the summed magnitude of the skin response to

all seven antigens. Based on the chart and information supplied with the simple skin test, basic anergy can be quickly assessed and quantified [221]. Unfortunately, this test cannot tell us where in the recognition/response chain of events the problem lies. However, specialized blood tests are now generally able to do that. Once this state of unresponsiveness has been confirmed, the next step in breaking anergy is with an immunotherapy protocol specific to the area(s) of immune response dysfunction as briefly described above.

2.5 Cancer Stem Cells

As a short overview, cancer stem cells (CSCs) are cancer cells (found within tumors or hematological cancers) that possess characteristics associated with normal stem cells, specifically the ability to give rise to all of the heterogeneous cancer cell lines found in a particular tumor. Targeting them is the fourth anti-cancer strategy. Until recently, attacking them would have been included in the general biochemical targeting strategy but recent research has shown them to be a separate and viable strategy. CSCs mediate tumor initiation, progression, and metastasis, and inhibiting them is an emerging new area of research to prevent, stop, and reverse tumor growth. They play key roles in tumor metastasis, drug resistance, and cancer relapse. Oncologic research has established that subpopulations of cells, identified by monoclonal antibodies to specific cell surface markers, behaved like developmental stem cells in their capacity to regrow the human tumors, for multiple generations, in experimental immune-deficient animal hosts. In all of the cancers studied so far, there is good evidence that CSCs are relatively resistant to radiation therapy and chemotherapy because of their slow rate of growth, indicating that novel CSC-targeted therapies are needed. Several pathways are promising targets against CSCs including inducing their apoptosis, inhibiting stem cell self-renewal to either stop their division or to promote their differentiation, or targeting the CSC milieu in the TME that supports them. The anti-CSC agents are categorized under two broad headings: small- and macromolecules with different subclasses such as kinase inhibitors and polypeptides. One of the first and safest agents to be recognized as a CSC inhibitor is Metformin [222-235].

Tumor initiation can either be driven by transformed differentiated cells or transformed

tissue-resident stem cells forming the new cancer stem cells [236,237]. As tissue stem cells already possess unlimited growth potential, it is believed that the transformation into a CSC requires only a very small number of genomic changes [238]. Multiple biomarkers that characterize CSCs have been identified and correlated to diagnosis, therapy, and prognosis [239]. They have been shown to display a high degree of plasticity, which changes their phenotypic and functional appearance making it harder to track them and predict their activity. Such shifts in their expression can be induced by chemo- and radiation therapy as well as by senescent tumor cells. Therapeutic regimens such as chemo- or radiation therapy shift the composition of tumor cell subpopulations changes by first killing some of the tumor cells, those with the highest proliferative capacity, causing a decrease in tumor size, while CSCs which multiply at a much slower rate survive. Instead of dying, some of the tumor cells will become senescent which causes further alterations in the tumor microenvironment that better support the CSCs [240].

The transformation to a cancer stem cell can take place during tissue regeneration or can be initiated and/or accelerated as a response to infections, toxins, radiation, or metabolic epigenetic influences that cause mutations [241]. During the process of transformation, oncogenes are overexpressed and tumor suppressor genes are inactivated, hence promoting the creation of, and uncontrolled growth of the CSCs. As a consequence of the transformative process, the affected cells “de-differentiate” and acquire stem cell self-renewal characteristics forming the nucleus of the cancer [242,243]. The mutations of the CSC progeny have a higher rate of replication which leads to the formation of a tumor [244].

Anti-CSC research has yielded some very promising therapeutic approaches. Nutraceuticals derived from herb and vegetable extracts show anti-CSC activity at various levels of clinical utility. Cruciferous vegetables belong to the *Cruciferae* family such as arugula, bok choy, broccoli, broccoli rabe, brussel sprouts, cabbage, and others, contain anti-cancer isothiocyanates including sulforaphane, that are enzymatically hydrolyzed from glucosinolates [245]. Normal dietary “doses” of isothiocyanate sulforaphane have been shown to have anti-CSC activity by altering phosphorylation of several kinases and their substrates including Glycogen synthase

kinase 3 (GSK3), Jun N-terminal Kinase (JNK), and Protein Kinase C (PKC) [246]. Soy isoflavones like genistein have been shown to have a potent anti-CSC effect by inhibiting the phosphorylation of Protein kinase B (AKT) and Forkhead Box O 3a (FOXO3a) [247]. Polyphenolic catechins including epigallocatechin-3-gallate (EGCG) found in green tea extracts have demonstrated anti-CSC activity, against a variety of cancers, through its ability to inhibit NF-κB activity, Mitogen-Activated Protein Kinase (MAPK) pathway, activator protein-1 (AP1) activity, and EGFR-mediated downstream signaling pathways [248,249]. Other anti-CSC nutraceuticals are derived from quercetin, curcumin, resveratrol, and ginger [250]. More potent anti-CSC pharmaceuticals are also derived from plant sources. Taxol is derived from the bark of the Pacific yew tree (*Taxus brevifolia*) and was discovered, through a random screening of approximately 15,000 species of plants, to have powerful anti-CSC activity against many different cancers [251]. Vinca alkaloids are a group of drugs that were originally extracted from the Madagascar periwinkle plant, *Catharanthus roseus* G. Don, and have anti-CSC activity as well as cytotoxic effects. There are three major vinca alkaloids in clinical use: Vinblastine (VBL), vinorelbine (VRL), and vincristine (VCR) [252].

Several pharmaceuticals have been “re-purposed” as anti-cancer agents when their anti-CSC “side-effect” was noticed. Studies have demonstrated that Metformin’s anti-cancer, anti-CSC effects go far beyond its ability to lower blood sugar in that Metformin impairs cellular metabolism and suppresses oncogenic signaling pathways, including tyrosine kinase receptors, PI3K/Akt, and mTOR pathways [253]. Furthermore, it suppressed the self-renewal ability of cancer stem cells and induced G0/G1 phase arrest by blocking the activity of cyclin-dependent kinases. In studies on osteosarcoma cancer cells Metformin-induced apoptosis through a mitochondria-dependent pathway, leading to the collapse of the mitochondrial transmembrane potential and the production of oxidatively destructive reactive oxygen species [254]. This destruction of the already compromised mitochondria further decreased ATP synthesis and triggered autophagy cancer cell death [255]. Thus, Metformin is an excellent addition to a metabolic strategy in that its activity is synergistic with the goals of further degrading the already damaged mitochondria in CSCs and cancer cells [256]. When combined with a beta-

blocker and aspirin the anti-CSC and anti-metastasis effects are even more pronounced [257,258].

Doxycycline too has been “re-purposed” for the fight against cancer. One of the FDA recognized side effects of doxycycline is the inhibition of mitochondrial biogenesis. Currently, in the <https://www.anticancerfund.org/en/redo-db> database, there is a listing of 356 “non-cancer drugs” which have shown some evidence of anticancer activity. Amongst them, doxycycline is high on the list of beneficial activity [259]. Sorting them out into a generally useful algorithm is a research project for WATSON, but for now, we have some important clues.

Doxycycline is a known inhibitor of the small mitochondrial ribosome (28S) and, as a consequence, is an inhibitor of mitochondrial protein translation necessary for biogenesis [260]. In vitro and in vivo evidence demonstrates the inhibitory effects of Doxycycline on cancer growth through mitochondrial destruction and the consequence of CSC suppression [261]. Azithromycin inhibits the large mitochondrial ribosome (39S) and enhanced the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) activity, which selectively targets tumor cells without damaging healthy cells as an off-target “side-effect” [262]. Together, these two antibiotics have a synergistic, anti-metabolic effect on CSCs that is greater than either one alone. We can add to the targeted anti-metabolic CSC effect with vitamin C that, in high dose IV’s (greater than 15 grams), acts as a pro-oxidant, which can produce free radicals further stressing the already dysfunctional mitochondria and hastening their destruction [263]. This combination of antibiotics and vitamin C has shown efficacy both in vitro and in vivo [264]. Further compromising the CSCs mitochondria leading to their destruction, seems to be an important process for stopping cancer. A shift from respiration to fermentation (glucose pathway) is not the only energy production shift that cancer cells, and in particular that CSCs can use, but it does seem to be an important and common one. To an extent, CSCs are metabolically flexible so multiple pathways may need to be blocked, often simultaneously, to minimize the risk of selective metabolic escape. In addition to inhibiting the major glucose pathway, as described above, fatty acids and glutamine can also be used by many CSCs to support their deranged metabolism. Lipophilic statins can inhibit the use of fatty acids as an

energy source for many types of cancer [265]. Hydroxychloroquine blocks cancer cells' ability to scavenge nutrients, including glutamine, through macropinocytosis, thereby closing yet another pathway for energy generation by the mutated cells [266]. Research on new anti-CSC strategies focuses on their signaling pathways and cellular communication system including; Hedgehog, Wnt/beta-catenin, Notch, Toll-like receptor 4 (TLR-4), Toll-like receptor 9 (TLR-9), Integrins, EGFR, IL-1, IL-6, Peroxisome proliferator-activated receptor (PPAR), and others.

CSCs and tumor cells, like all eukaryotic cells, produce structures called exosomes in their endosomal compartment [267]. They are approximately 100 nm in diameter and are surrounded by a lipid bilayer membrane. Exosomes have been recognized as potent vehicles of intercellular communication due to their capacity to transfer proteins, lipids, and nucleic acids; thereby influencing various physiological and pathological functions of both recipient and parent cells [268]. The involvement of exosomes in the phenotype transformation from non-CSC to CSC has been recently evidenced by research on the X chromosome long non-coding RNA, which is overexpressed in malignant tumor tissues and activates Toll-like receptor (TLR) 7 and NF- κ B inflammatory signaling [269].

Exosomes have been reported to interact with the cells of the immune system, modulating and downregulating its response thus allowing for tumor progression [270]. Tumor-derived exosomes (TEXs) induce apoptosis of the activated CD8+ (cluster of differentiation 8) T cells (which have an anti-cancer surveillance function), suppress natural killer (NK) cell activity, promote the induction of regulatory T cells (Tregs) and myeloid-derived suppressor cells, and interfere with monocyte differentiation into anti-cancer dendritic cells [271]. While TEXs form the immunosuppressive microenvironment, Treg-derived exosomes inhibit the induction of cytotoxic T lymphocytes, further allowing for the growth and spread of the tumor [272]. As a result of the research on tumor cell exosomes, they have become a promising target for the treatment of cancer but as of yet this therapy is not available [273-276].

2.6 Cytotoxic Cancer Therapy

Cytotoxic cancer treatments are traditionally covered by the term chemotherapy and have

come to imply the use of agents that act, separately from the body at large, as intracellular poisons to inhibit mitosis or directly induce some sort of cell death and is the fifth anti-cancer strategy. Substances that accomplish this as a secondary effect through blocking extracellular signals or which act through a specific genetic, enzymatic, or hormonal pathway are excluded from this therapeutic strategy as they are referred to as targeted therapies and elsewhere described. Chemotherapeutic agents are characteristically purified to the point of being a chemical, and may be of natural origin or synthetically created. The deliberate use of natural, herbal source agents began in the early 1920s, including *Viscum* alkaloids and lectins, and they are still used today, whereas the first synthetic agent, nitrogen mustard, was "discovered accidentally" during World War II when it was observed that it could shrink lymphoma tumors in mice. A few years later, it was discovered that alkaloids extracted from the *Vinca rosea* plant were useful in treating Hodgkin's disease, and so a multibillion dollar industry was birthed creating and extracting new substances helpful in the "war on cancer". Unfortunately, many of these substances have similar effects on healthy cells, thus creating a multitude of side effects and limiting their usefulness. Newer protocols that use lower doses of these agents, such as metronomic or insulin potentiated chemotherapy, are showing good results with far fewer side effects. Metronomic, low dose chemotherapy has been in development for two decades and seems to act through several mechanisms including inhibiting the growth of new blood vessels, the restoration of an anticancer immune response, and the induction of tumor dormancy. Whereas Insulin Potentiated Therapy (IPT), another low dose strategy, takes physiologic advantage of the excessive number of insulin receptors found on the cell surface of cancer cells. Giving insulin just prior to the infusion of low dose chemotherapeutic agents, usually in a combination designed to intervene at several sites of the cell cycle, causes much fewer side effects and can hold the cancer at bay, while buying time to reconstitute an effective immune response or integrate another anti-cancer therapeutic strategy. IPT has been in development and clinical use since the 1930s and has been used to help treat other chronic diseases as well [277-290].

Cytotoxic chemotherapy is usually administered as per a protocol derived by treating a group of

people (cohorts) with a similar diagnosis. These clinical trials are done to determine the general dose and combination of agents that are most effective and least toxic according to the structure of the trial for that disease diagnosis. This approach is designed to attack different genetic targets and the aspects of DNA transcription of rapidly dividing cells [291-293]. A more contemporary way for using cytotoxic agents is to target them so that the agents affect biochemical factors or cellular pathways that are unique to the malignant cells or characteristic of tumors based upon genetic studies.

Cytotoxic chemotherapy can be very good at killing rapidly dividing cells, such as those found in a growing tumor, but are not good at killing the slow-growing cancer stem cells that are at the root of the problem. This leads to the observed high risk for recurrence and to eventual multi-drug resistance [294]. There is a great deal of research currently engaged in addressing this problem and certain drug combinations have been found that can lessen this issue by making the cytotoxic response more effective [295]. At this point, we know that P-glycoprotein (also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1)) plays a crucial role in determining the neutralizing response against chemotherapy. P-glycoprotein (p-gp) acts as an ATP-dependent pump that pumps out small molecules from cells, including chemotherapeutic agents, before they can exert their cytotoxic effects. Research demonstrates that p-glycoprotein expression levels correlate inversely with drug efficacy, which suggests the rationale for developing p-glycoprotein inhibitors for treatment against cancer [296]. While new agents are being developed and going through drug trials, some currently available pharmaceuticals are helpful against multi-drug resistance. Verapamil is an L-type calcium channel blocker with antiarrhythmic, antianginal, and antihypertensive activity, but is also a p-gp inhibitor. Unfortunately, the dose required to achieve this effect can cause significant hypotension thus limiting its usefulness [297]. Other agents that may be helpful are to be found within the class of drugs known as proton pump inhibitors (PPIs) [298].

Proton pump inhibitors (PPIs) given before the chemotherapy have been shown to inhibit mRNA levels of vacuolar-type ATPase (V-ATPases), multidrug resistance mutation 1 (MDR1), multidrug resistance protein 1 (MRP1), phosphatidylinositol 3-kinases (PI3K), Akt, mTOR, and HIF-1 α . PPIs inhibited V-ATPases

and down-regulated the expressions of P-gp and MRP1 in a dose-dependent manner both in vitro and in vivo [299].

There are also low concentration natural agents that are cytotoxic to cancer cells that may be used with low doses of cytotoxic chemotherapy to reduce side effects and improve the quality of life. In use for a 100 years, research has shown that *Viscum album* (mistletoe) extracts (VAE) have a significant positive impact on the quality of life and the reduction of the side effects from conventional therapies (chemotherapy, radiation) in experimental trials as well as in routine daily application [300,301]. Furthermore, pooled data from multiple clinical studies demonstrate that adjuvant treatment of cancer patients with the VAE is associated with better overall survival [302]. In some cases not only is VAE effective as an additional cytotoxic, anti-cancer agent, but it may succeed when more conventional chemotherapy and immunotherapy have failed [303-310].

Another important benefit of VAE is its ability to overcome some scenarios of chemoresistance. Axl protein is a receptor for tyrosine kinases. Some reports showed that targeting anelexleto (Axl) enhanced EGFR TKI response in selected EGFR wild type (WT) NSCLC patients. Studies have found that when targeting Axl in EGFR WT NSCLC cells, the cells showed a more sensitive response to erlotinib than those that overexpressed Axl thereby overcoming chemoresistance [311,312].

Chemoresistance is a big problem with chemotherapy as the agents seem to have an almost evolutionary effect on tumors, selecting for the most sensitive cancer cells and leaving the rest, including the CSCs untouched, or more mutated, therein setting the stage for a recurrence. Radiation therapy has similar drawbacks. Doxycycline is helpful with both treatment modalities to reduce chemoresistance, largely through interrupting oxidative phosphorylation by inhibiting moieties of the electron transport chain [313,314]. This brings us back to the necessity for targeting CSCs to help overcome chemoresistance [315-319].

Another cytotoxic strategy that generates much less chemoresistance because it also targets CSCs is the use of vitamin C (VC) and vitamin K(3) (VK(3)). administered intravenously in a VC:VK(3) ratio of 100:1 exhibit synergistic antitumor activity and preferentially kills tumor

cells without harming normal cells [320]. This natural vitamin combination accomplishes this through a process of autoschizis, a novel type of necrosis characterized by exaggerated membrane damage and progressive loss of organelle-free cytoplasm through a series of self-excisions [321]. This combination also attacks the DNA of cancer cells since a deficiency of alkaline and acid DNase is a hallmark in all living cancer cells and they are reactivated in the early stages of cancer cell death by vitamin C (acid DNase) and vitamin K(3) (alkaline DNase) leading to DNA fragmentation [322]. Vitamin C by itself can regulate the proliferation and differentiation of cancer stem cells, the amount and stability of collagen, extracellular matrix remodeling, anti-cancer immunity, and hypoxia in the tumor microenvironment, hence epigenetically suppressing the CSCs and downregulating chemoresistance [323-326]. When combined with doxycycline, the effect is even more pronounced [327,328].

2.7 Supportive Tactics

There are other therapeutic tactics that may be synergistic, but they are not considered strategies unto themselves because their anti-cancer effects are less reliable. This includes energy-based therapies such as homeopathy and acupuncture, and psychodynamic tactics like psychoneuroimmunology, visualization, prayer, and meditation practices. Other tactics employ the use of oncolytic viruses, oxidative therapies (ozone), Traditional Chinese Medicine, Naturopathy, Ayurvedic herbal medicines, and detoxification protocols, to name but a few. There is no doubt that some of them can be extraordinarily beneficial to the patient by reducing physical symptoms, psychological stress and by engendering a feeling of more self-control against a disease that threatens total chaos. Indeed hundreds of books and articles have been scribed as to their use and intermittent efficacy by notable physicians and practitioners; to this day the well-documented phenomena of the spontaneous remission of cancer remains a medical mystery. Early in my career, the immunotherapeutic strategy that I employed against cancer was still considered something just short of quackery, and the clinical responses to it were often attributed to this phenomenon.

3. DISCUSSION

An evidence-based medical practice is established through the application and

integration of the best clinical research available at the time, balanced with the clinicians' expertise and the patients' life values and beliefs [329]. Evidence-based medicine may be considered as an interdisciplinary approach itself, which uses techniques from science, engineering, biostatistics, and epidemiology, such as meta-analysis, decision analysis, risk-benefit analysis, verified case reports, and randomized controlled trials to deliver "the right care at the right time to the right patient" [330]. Every time that a physician treats a patient for anything, it is essentially a clinical trial with an "n" of 1. Thus the practice of evidence-based medicine tacitly dictates that physicians should make "conscientious, explicit, and judicious use of their understanding of the best medical information available" for the validation of the proposed treatment and its application in patient care in partnership with the patient and their expectations [331].

Cancer is a serious and often life-threatening disease that deserves careful consideration of the benefits and long-term risks of each of these five strategic approaches, evolving beyond cohort-based trials into an integrated, personalized approach for the treatment of each patient. Champions for the exclusive use of any one of these strategies abound, but it is my belief and experience that the best answer for cancer, for any one patient, will be found in their integration into an individualized cohesive clinical protocol.

Research is needed to codify the algorithm necessary for applying the best integrative therapeutic strategy given the dynamics of the cancer and the patient's biochemistry, genetics, and immunology at any given point in their treatment.

4. CONCLUSION

Cancer, as a disease of our time, has been described as a "wound that does not heal" and is characterized as having numerous biochemical dysfunctions at its core, which lead to a multitude of genetic aberrations and pathologic phenotypic expression. However, in order for these genetically and phenotypically abnormal cells to survive and thrive, the watchdog of the body, the immune system, must itself be suffering from a number of serious areas of structural and functional damage. There are many tactics that can support the therapeutic strategies briefly described above, and they should be applied in an integrative manner as they are nonexclusive

with each other and can be mutually supportive [332]. However, more aggressive cytotoxic strategies, i.e., full-dose chemotherapy and radiation, can render many of these strategies null and void but may be considered for possible later use. When treating cancer, the physician and patient should make the decisions together, since the stakes can be no higher, using the best information available at the time, and then never look back. When treating cancer there is but one direction to go and that is forward, striving for ever-increasing improvements in the quality and quantity of life with the hope of achieving a durable remission [333-336].

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENTS

I would like to thank Summer A. Stoff, B.A., and Colleen A. Murtha-Stoff, N.P. for their highly valued editing skills in preparing this manuscript.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Byun, Gardner K. Wounds that will not heal. *Am J Pathol.* 2013 Apr;182(4):1055–1064.
DOI: 10.1016/j.ajpath.2013.01.009
PMID: 23438473.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell.* 2011 Mar 4;144(5):646-74.
DOI: 10.1016/j.cell.2011.02.013
PMID: 21376230
3. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000 Jan 7;100(1):57-70.
DOI: 10.1016/s0092-8674(00)81683-9
PMID: 10647931
4. Available: <https://www.atsdr.cdc.gov/emes/public/docs/Chemicals,%20Cancer,%20and%20You%20FS.pdf>
5. Seyfried T, Flores R, Poff A, D'Agostino D. Cancer as a metabolic disease: implications for novel therapeutics. *Carcinogenesis.* 2014 Mar;35(3):515–527.
PMID: 24343361.
6. Seyfried T. Cancer as a mitochondrial metabolic disease. *Front Cell Dev Biol.* 2015;3:43.
PMID: 26217661
7. Seyfried T. Cancer as a metabolic disease: On the origin, management, and prevention of cancer. Wiley. 1st edition (June 26, 2012), N.Y., ISBN-10:0470584920.
8. Available: <https://www.mayoclinichealthsystem.org/hometown-health/speaking-of-health/healthy-food-and-a-healthy-lifestyle-can-help-prevent-cancer>
9. Available: <https://stanfordhealthcare.org/medical-clinics/cancer-nutrition-services/recipes.html>
10. Available: <https://www.mdanderson.org/prevention-screening/manage-your-risk/diet.html>
11. Baudry J, Assmann KE, Touvier M, Allès B, Seconda L, Latino-Martel P, Ezzedine K, Galan P, Hercberg S, Lairon D, Kesse-Guyot E. Association of frequency of organic food consumption with cancer risk: Findings from the NutriNet-Santé prospective cohort study. *JAMA Intern Med.* 2018 Dec 1;178(12):1597-1606.
DOI: 10.1001/jamainternmed.2018.4357
Erratum in: *JAMA Intern Med.* 2018 Dec 1;178(12):1732.
PMID: 30422212;
PMCID: PMC6583612.
12. Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer - Where do we stand? *Mol Metab.* 2020 Mar;33:102-121.
DOI: 10.1016/j.molmet.2019.06.026
Epub 2019 Jul 27.
PMID: 31399389;
PMCID: PMC7056920.
13. Quillin P. Beating Cancer with Nutrition, Nutrition Times Press Inc; 4th edition; 2020.
ISBN 978-1-7352347-0-0.
14. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: A therapeutic opportunity in breast cancer. *Clin Cancer Res.* 2010 Mar 15;16(6):1695-700.
DOI: 10.1158/1078-0432.CCR-09-1805
Epub 2010 Mar 9.
PMID: 20215559;
PMCID: PMC2840206.

15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest.* 2001 Oct;108(8):1167-74.
DOI: 10.1172/JCI13505
PMID: 11602624;
PMCID: PMC209533.
16. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science.* 2005 Dec 9;310(5754):1642-6.
DOI: 10.1126/science.1120781
Epub 2005 Nov 24.
PMID: 16308421;
PMCID: PMC3074427.
17. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. *Circ Res.* 2007 Feb 16;100(3):328-41.
DOI:10.1161/01.RES.0000256090.42690.05
PMID: 17307971.
18. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. *Cancer Cell.* 2007 Jul;12(1):9-22.
DOI: 10.1016/j.ccr.2007.05.008
PMID: 17613433.
19. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG. Metformin: Taking away the candy for cancer? *Eur J Cancer.* 2010 Sep;46(13):2369-80.
DOI: 10.1016/j.ejca.2010.06.012
Epub 2010 Jul 23.
PMID: 20656475.
20. Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. *Anticancer Res.* 2012;32(5):1627-37.
PMID: 22593441.
21. Hoesel B, Schmid JA. The complexity of NF- κ B signaling in inflammation and cancer. *Mol Cancer.* 2013 Aug 2;12:86.
DOI: 10.1186/1476-4598-12-86
PMID: 23915189;
PMCID: PMC3750319.
22. Shemenski J. Cimetidine as a novel adjunctive treatment for early stage Lyme disease. *Med Hypotheses.* 2019 Jul;128:94-100.
DOI: 10.1016/j.mehy.2016.03.015
Epub 2016 Apr 9.
PMID: 27107653.
23. Kotsafti A, Scarpa M, Castagliuolo I, Scarpa M. Reactive oxygen species and antitumor immunity-from surveillance to evasion. *Cancers (Basel).* 2020 Jul 1;12(7):1748.
DOI: 10.3390/cancers12071748
PMID: 32630174;
PMCID: PMC7409327.
24. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. *Proc Natl Acad Sci U S A.* 2013 Jan 15;110(3):972-7.
DOI: 10.1073/pnas.1221055110
Epub 2012 Dec 31.
PMID: 23277563;
PMCID: PMC3549132.
25. Prasad S, Ravindran J, Aggarwal BB. NF- κ B and cancer: How intimate is this relationship. *Mol Cell Biochem.* 2010 Mar;336(1-2):25-37.
DOI: 10.1007/s11010-009-0267-2
Epub 2009 Oct 8.
PMID: 19823771;
PMCID: PMC3148942.
26. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. *Cancer Res.* 2011 May 1;71(9):3196-201.
DOI: 10.1158/0008-5472.CAN-10-3471
Epub 2011 Mar 17.
PMID: 21415163;
PMCID: PMC3085572.
27. Rosa R, D'Amato V, De Placido S, Bianco R. Approaches for targeting cancer stem cells drug resistance. *Expert Opin Drug Discov.* 2016 Dec;11(12):1201-1212.
DOI: 10.1080/17460441.2016.1243525
Epub 2016 Oct 14.
PMID: 27700193.
28. Dragu DL, Necula LG, Bleotu C, Diaconu CC, Chivu-Economescu M. Therapies targeting cancer stem cells: Current trends and future challenges. *World J Stem Cells.* 2015 Oct 26;7(9):1185-201.
DOI: 10.4252/wjsc.v7.i9.1185
PMID: 26516409;

- PMCID: PMC4620424.
29. Clavo B, Pérez JL, López L, Suárez G, Lloret M, Rodríguez V, Macías D, Santana M, Hernández MA, Martín-Oliva R, Robaina F. Ozone therapy for Tumor oxygenation: A pilot study. *Evid Based Complement Alternat Med.* 2004 Jun 1;1(1):93-98.
DOI: 10.1093/ecam/neh009
PMID: 15257330;
PMCID: PMC442111.
 30. Sweet F, Kao MS, Lee SC, Hagar WL, Sweet WE. Ozone selectively inhibits growth of human cancer cells. *Science.* 1980 Aug 22;209(4459):931-3.
DOI: 10.1126/science.7403859
PMID: 7403859.
 31. Bocci V, Larini A, Micheli V. Restoration of normoxia by ozone therapy may control neoplastic growth: A review and a working hypothesis. *J Altern Complement Med.* 2005 Apr;11(2):257-65.
DOI: 10.1089/acm.2005.11.257
PMID: 15865491.
 32. Luongo M, Brigida AL, Mascolo L, Gaudino G. Possible therapeutic effects of ozone mixture on hypoxia in tumor development. *Anticancer Res.* 2017 Feb;37(2):425-435.
DOI: 10.21873/anticancer.11334
PMID: 28179287.
 33. Cooke M, Iosia M, Buford T, Shelmadine B, Hudson G, Kerksick C, Rasmussen C, Greenwood M, Leutholtz B, Willoughby D, Kreider R. Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. *J Int Soc Sports Nutr.* 2008 Mar 4;5:8.
DOI: 10.1186/1550-2783-5-8
PMID: 18318910;
PMCID: PMC231563
 34. Smith NL, Wilson AL, Gandhi J, Vatsia S, Khan SA. Ozone therapy: An overview of pharmacodynamics, current research, and clinical utility. *Med Gas Res.* 2017 Oct 17;7(3):212-219.
DOI: 10.4103/2045-9912.215752
PMID: 29152215;
PMCID: PMC5674660.
 35. Re L, Mawsouf MN, Menéndez S, León OS, Sánchez GM, Hernández F. Ozone therapy: Clinical and basic evidence of its therapeutic potential. *Arch Med Res.* 2008 Jan;39(1):17-26.
DOI: 10.1016/j.arcmed.2007.07.005
Epub 2007 Sep 29.
PMID: 18067991.
 36. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. *Atheroscler Suppl.* 2005 May;6(2):21-9.
DOI:10.1016/j.atherosclerosissup.2005.02.005
PMID: 15823493.
 37. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. *Cancer Epidemiol Biomarkers Prev.* 2005 Oct;14(10):2413-8.
DOI: 10.1158/1055-9965.EPI-05-0316
PMID: 16214925.
 38. Coussens LM, Werb Z. Inflammation and cancer. *Nature.* 2002 Dec 19-26;420(6917):860-7.
DOI: 10.1038/nature01322
PMID: 12490959;
PMCID: PMC2803035.
 39. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. *Ann Afr Med.* 2019 Jul-Sep;18(3):121-126.
DOI: 10.4103/aam.aam_56_18
PMID: 31417011;
PMCID: PMC6704802.
 40. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. *Prostate.* 2000 Jan;42(1):73-8.
DOI: 10.1002/(sici)1097-0045(20000101)42:1<73::aid-pros9>3.0.co;2-g
PMID: 10579801.
 41. Chen YJ, Wang LS, Wang PH, Lai CR, Yen MS, Ng HT, Yuan CC. High cyclooxygenase-2 expression in cervical adenocarcinomas. *Gynecol Oncol.* 2003 Mar;88(3):379-85.
DOI: 10.1016/s0090-8258(02)00066-5
PMID: 12648590.
 42. Cheng H, Lu C, Tang R, Pan Y, Bao S, Qiu Y, Xie M. Ellagic acid inhibits the proliferation of human pancreatic carcinoma PANC-1 cells in vitro and in vivo. *Oncotarget.* 2017 Feb 14;8(7):12301-12310.
DOI: 10.18632/oncotarget.14811
PMID: 28135203;
PMCID: PMC5355345.
 43. Maroon JC, Bost JW, Maroon A. Natural anti-inflammatory agents for pain relief. *Surg Neurol Int.* 2010 Dec 13;1:80.
DOI: 10.4103/2152-7806.73804

- PMID: 21206541;
PMCID: PMC3011108.
44. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, Dagenais GR. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: A randomized placebo-controlled study. *Circulation*. 2004 Aug 24;110(8):934-9.
DOI:10.1161/01.CIR.0000139338.12464.5F
Epub 2004 Aug 9.
PMID: 15302800.
 45. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. *Cancer Lett*. 2013 May 28;332(2):313-24.
DOI: 10.1016/j.canlet.2011.01.012
Epub 2011 Feb 22.
PMID: 21345578.
 46. Cancer Research UK, Feeling the heat-the link between inflammation and cancer. Available:<https://scienceblog.cancerresearchuk.org/2013/02/01/feeling-the-heat-the-link-between-inflammation-and-cancer/>
Accessed: 9/10/21
 47. National Cancer Institute, Cancer-causing Substances in the Environment. Available:<https://www.cancer.gov/about-cancer/causes-prevention/risk/substances>
Accessed: 9/10/21
 48. Chemicals, Cancer, and You. Available:<https://www.atsdr.cdc.gov/emes/public/docs/Chemicals,%20Cancer,%20and%20You%20FS.pdf>
Accessed: 9/10/21
 49. American Cancer Society, Known and Probably Human Carcinogens. Available:<https://www.cancer.org/cancer/cancer-causes/general-info/known-and-probable-human-carcinogens.html>
Accessed: 9/10/21
 50. Hosseini M, Houshmand M, Ebrahimi A. MTHFR polymorphisms and breast cancer risk. *Arch Med Sci*. 2011 Feb;7(1):134-7.
DOI: 10.5114/aoms.2011.20618
Epub 2011 Mar 8.
PMID: 22291746;
PMCID: PMC3258688.
 51. What Does the MTHFR Gene Mutation Cause? Available:https://www.medicinenet.com/what_does_the_mthfr_gene_mutation_cause/article.htm
 52. Wajed SA, Laird PW, DeMeester TR. DNA methylation: An alternative pathway to cancer. *Ann Surg*. 2001 Jul;234(1):10-20.
DOI: 10.1097/00000658-200107000-00003
PMID: 11420478;
PMCID: PMC1421942.
 53. Brasky TM, White E, Chen CL. Long-term, supplemental, one-carbon metabolism-related Vitamin B Use in relation to lung cancer risk in the Vitamins and Lifestyle (VITAL) Cohort. *J Clin Oncol*. 2017 Oct 20;35(30):3440-3448.
DOI: 10.1200/JCO.2017.72.7735
Epub 2017 Aug 22.
PMID: 28829668;
PMCID: PMC5648175.
 54. Peterson CT, Rodionov DA, Osterman AL, Peterson SN. B Vitamins and their role in immune regulation and cancer. *Nutrients*. 2020 Nov 4;12(11):3380.
DOI: 10.3390/nu12113380
PMID: 33158037;
PMCID: PMC7693142.
 55. Available:<https://www.medicalnewstoday.com/articles/324863#risk-factors>
 56. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? *Free Radic Biol Med*. 2010 Dec 1;49(11):1603-16.
DOI: 10.1016/j.freeradbiomed.2010.09.006
Epub 2010 Sep 16.
PMID: 20840865;
PMCID: PMC2990475.
 57. Duwe AK, Werkmeister J, Roder JC, Lauzon R, Payne U. Natural killer cell-mediated lysis involves an hydroxyl radical-dependent step. *J Immunol*. 1985 Apr;134(4):2637-44.
PMID: 2982948.
 58. Wang J, Yi J. Cancer cell killing via ROS: To increase or decrease, that is the question. *Cancer Biol Ther*. 2008 Dec;7(12):1875-84.
DOI: 10.4161/cbt.7.12.7067
Epub 2008 Dec 24.
PMID: 18981733.
 59. Kim SJ, Kim HS, Seo YR. Understanding of ROS-inducing strategy in anticancer therapy. *Oxid Med Cell Longev*. 2019 Dec 18;2019:5381692.
DOI: 10.1155/2019/5381692
PMID: 31929855;
PMCID: PMC6939418.
 60. Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A. ROS in cancer

- therapy: The bright side of the moon. *Exp Mol Med*. 2020 Feb;52(2):192-203.
DOI: 10.1038/s12276-020-0384-2
Epub 2020 Feb 14.
PMID: 32060354;
PMCID: PMC7062874.
61. Liou GY, Storz P. Reactive oxygen species in cancer. *Free Radic Res*. 2010 May;44(5):479-96.
DOI: 10.3109/10715761003667554
PMID: 20370557;
PMCID: PMC3880197.
 62. Hegedűs C, Kovács K, Polgár Z, Regdon Z, Szabó É, Robaszkievicz A, Forman HJ, Martner A, Virág L. Redox control of cancer cell destruction. *Redox Biol*. 2018 Jun;16:59-74.
DOI: 10.1016/j.redox.2018.01.015
Epub 2018 Feb 3.
PMID: 29477046;
PMCID: PMC5842284.
 63. Siegers CP, Andresen S, Keogh JP. Does cimetidine improve prospects for cancer patients?. A reappraisal of the evidence to date. *Digestion*. 1999 Sep-Oct;60(5):415-21.
DOI: 10.1159/000007686
PMID: 10473965.
 64. NavaneethaKrishnan S, Rosales JL, Lee KY. ROS-Mediated Cancer cell killing through dietary phytochemicals. *Oxid Med Cell Longev*. 2019 May 14;2019:9051542.
DOI: 10.1155/2019/9051542
PMID: 31217841;
PMCID: PMC6536988.
 65. Sharif T, et al. The polyphenolic-rich *Aronia melanocarpa* juice kills teratocarcinoma cancer stem-like cells, but not their differentiated counterparts. *Journal Of Functional Foods*; July 2013.
DOI: 10.1016/j.jff.2013.04.007
 66. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative stress: Harms and benefits for human health. *Oxid Med Cell Longev*. 2017;2017:8416763.
DOI: 10.1155/2017/8416763
Epub 2017 Jul 27.
PMID: 28819546;
PMCID: PMC5551541.
 67. Kheirandish M, Mahboobi H, Yazdanparast M, Kamal W, Kamal MA. Anti-cancer effects of metformin: Recent evidences for its role in prevention and treatment of cancer. *Curr Drug Metab*. 2018;19(9):793-797.
DOI:10.2174/1389200219666180416161846
PMID: 29663879.
 68. Aljofan M, Riethmacher D. Anticancer activity of metformin: A systematic review of the literature. *Future Sci OA*. 2019 Aug 22;5(8):FSO410.
DOI: 10.2144/fsoa-2019-0053
PMID: 31534778;
PMCID: PMC6745597.
 69. Wang Y, Liu Y, Du X, Ma H, Yao J. The Anti-cancer mechanisms of Berberine: A review. *Cancer Manag Res*. 2020 Jan 30;12:695-702.
DOI: 10.2147/CMAR.S242329
PMID: 32099466;
PMCID: PMC6996556.
 70. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: A systemic review and meta-analysis. *Evid Based Complement Alternat Med*. 2012;2012:591654.
DOI: 10.1155/2012/591654
Epub 2012 Oct 15.
PMID: 23118793;
PMCID: PMC3478874.
 71. Patel SM, Nagulapalli Venkata KC, Bhattacharyya P, Sethi G, Bishayee A. Potential of neem (*Azadirachta indica* L.) for prevention and treatment of oncologic diseases. *Semin Cancer Biol*. 2016 Oct;40-41:100-115.
DOI: 10.1016/j.semcancer.2016.03.002
Epub 2016 Mar 24.
PMID: 27019417.
 72. Khosla P, Bhanwra S, Singh J, Seth S, Srivastava RK. A study of hypoglycaemic effects of *Azadirachta indica* (Neem) in normal and alloxan diabetic rabbits. *Indian J Physiol Pharmacol*. 2000 Jan;44(1):69-74.
PMID: 10919098.
 73. Mishan MA, Khazeei Tabari MA, Zargari M, Bagheri A. MicroRNAs in the anticancer effects of celecoxib: A systematic review. *Eur J Pharmacol*. 2020 Sep 5;882:173325.
DOI: 10.1016/j.ejphar.2020.173325
Epub 2020 Jun 29.
PMID: 32615181.
 74. Carter A. Curry compound fights cancer in the clinic. *J Natl Cancer Inst*. 2008 May 7;100(9):616-7.
DOI: 10.1093/jnci/djn141

- Epub 2008 Apr 29.
PMID: 18445813.
75. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. *Adv Exp Med Biol.* 2007;595:105-25. DOI: 10.1007/978-0-387-46401-5_3 PMID: 17569207.
 76. Nallathambi R, Poulev A, Zuk JB, Raskin I. Proanthocyanidin-rich grape seed extract reduces inflammation and oxidative stress and restores tight junction barrier function in Caco-2 colon cells. *Nutrients.* 2020 Jun 1;12(6):1623. DOI: 10.3390/nu12061623 PMID: 32492806; PMCID: PMC7352846.
 77. Wang H, Khor TO, Shu L, Su ZY, Fuentes F, Lee JH, Kong AN. Plants vs. cancer: A review on natural phytochemicals in preventing and treating cancers and their druggability. *Anticancer Agents Med Chem.* 2012 Dec;12(10):1281-305. DOI: 10.2174/187152012803833026 PMID: 22583408; PMCID: PMC4017674.
 78. Kubecova M, Kolostova K, Pinterova D, Kacprzak G, Bobek V. Cimetidine: An anticancer drug? *Eur J Pharm Sci.* 2011 Apr 18;42(5):439-44. DOI: 10.1016/j.ejps.2011.02.004 Epub 2011 Feb 15. PMID: 21329756.
 79. Hegde P, Maddur MS, Friboulet A, Bayry J, Kaveri SV. *Viscum album* exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. *PLoS One.* 2011;6(10):e26312. DOI: 10.1371/journal.pone.0026312 Epub 2011 Oct 18. PMID: 22028854; PMCID: PMC3196571.
 80. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. *Clin Cancer Res.* 2009 Jun 1;15(11):3881-8. DOI: 10.1158/1078-0432.CCR-08-2196 Epub 2009 May 26. PMID: 19470736.
 81. Akone SH, Ntie-Kang F, Stuhldreier F, Ewonkem MB, Noah AM, Mouelle SEM, Müller R. Natural products impacting DNA Methyltransferases and Histone Deacetylases. *Front Pharmacol.* 2020 Aug 13;11:992. DOI: 10.3389/fphar.2020.00992 PMID: 32903500; PMCID: PMC7438611.
 82. Sanmartín-Suárez C, Soto-Otero R, Sánchez-Sellero I, Méndez-Álvarez E. Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants. *J Pharmacol Toxicol Methods.* 2011 Mar-Apr;63(2):209-15. DOI: 10.1016/j.vascn.2010.10.004 Epub 2010 Nov 6. PMID: 21059397.
 83. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. *Menopause.* 2003 Mar-Apr;10(2):142-6. DOI: 10.1097/00042192-200310020-00005 PMID: 12627039.
 84. Frei B, McCall MR. Antioxidant vitamins: Evidence from biomarkers in humans. *Bibl Nutr Dieta.* 2001;(55):46-67. DOI: 10.1159/000059462 PMID: 11125585.
 85. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer.* 2009 Apr;9(4):239-52. DOI: 10.1038/nrc2618 Epub 2008 Mar 12. PMID: 19279573; PMCID: PMC3251309.
 86. Available:<https://www.news-medical.net/life-sciences/What-is-the-Tumor-Microenvironment.aspx>
 87. Hanahan D, Coussens LM. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. *Cancer Cell.* 2012 Mar 20;21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022 PMID: 22439926.
 88. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C. Role of tumor microenvironment in tumorigenesis. *Journal of Cancer [online].* 2017;8(5):761-773. Available:<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381164/>
 89. Available:<https://www.natera.com/oncology/signatera-advanced-cancer-detection/>
 90. Frisch J, Angenendt A, Hoth M, Prates Roma L, Lis A. STIM-Orai channels and reactive oxygen species in the tumor

- microenvironment. *Cancers (Basel)*. 2019 Mar 30;11(4):457.
DOI: 10.3390/cancers11040457
PMID: 30935064;
PMCID: PMC6520831.
91. Balkwill F, Capasso M, Hagemann T. The tumor microenvironment at a glance. *Journal of Cell Science*, [online]. 2012;125(23):5591-5596.
Available: <https://jcs.biologists.org/content/125/23/5591>
PMID: 23420197.
 92. Hao G, Zhi Ping Xu and Li Li. Manipulating extracellular tumour pH: An effective target for cancer therapy (Review Article). *RSC Adv*. 2018;8:22182-22192.
DOI: 10.1039/C8RA02095G
 93. Richard Sollazzo, M.D. DABIM, CNS, DAAM, FAAM, personal communication, 8/14/21.
 94. Yang M, Zhong X, Yuan Y. Does baking soda function as a magic bullet for patients with cancer? A mini review. *Integr Cancer Ther*. 2020 Jan-Dec;19:1534735420922579.
DOI: 10.1177/1534735420922579
PMID: 32448009;
PMCID: PMC7249593.
 95. Nordenström BEW. Electrochemical treatment of cancer. *Annales de Radiologie*. 1985;28:128-129.
 96. Nordenström B. Electrochemical treatment of cancer. I: Variable response to anodic and cathodic fields. *Am J Clin Oncol*. 1989 Dec;12(6):530-6.
PMID:2556014.
 97. Xin Y, Xue F, Ge B, Zhao F, Shi B, Zhang W. Electrochemical treatment of lung cancer. *Bioelectromagnetics*. 1997;18(1):8-13.
PMID: 9125236.
 98. Gweon EJ, Kim SJ. Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. *Oncol Rep*. 2014 Jul;32(1):71-8.
DOI: 10.3892/or.2014.3192
Epub 2014 May 16.
PMID: 24841706.
 99. Yu HB, Zhang HF, Zhang X, Li DY, Xue HZ, Pan CE, Zhao SH. Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism. *Hepatogastroenterology*. 2010 Sep-Oct;57(102-103):1241-6.
PMID: 21410066.
 100. Zhang C, Kim SK. Matrix metalloproteinase inhibitors (MMPi) from marine natural products: The current situation and future prospects. *Mar Drugs*. 2009 Mar 31;7(2):71-84.
DOI: 10.3390/md7020071
PMID: 19597572;
PMCID: PMC2707034.
 101. Available: <https://www.cancer.gov/publications/dictionaries/cancer-drug/def/shark-cartilage-extract-ae-941>
 102. Kunte M, Desai K. The protein extract of *Chlorella minutissima* inhibits the expression of MMP-1, MMP-2 and MMP-9 in cancer cells through upregulation of TIMP-3 and down regulation of c-Jun. *Cell J*. 2018 Jul;20(2):211-219.
DOI: 10.22074/cellj.2018.5277
Epub 2018 Mar 18.
PMID: 29633599;
PMCID: PMC5893293.
 103. Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: Potential for the development of new therapeutics. *Cells*. 2020 May 25;9(5):1313.
DOI: 10.3390/cells9051313
PMID: 32466129;
PMCID: PMC7290391.
 104. Cione E, La Torre C, Cannataro R, Caroleo MC, Plastina P, Gallelli L. Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From dietary sources to human MicroRNA modulation. *Molecules*. 2019 Dec 23;25(1):63.
DOI: 10.3390/molecules25010063
PMID: 31878082;
PMCID: PMC6983040.
 105. Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. Micronutrient synergy--A new tool in effective control of metastasis and other key mechanisms of cancer. *Cancer Metastasis Rev*. 2010 Sep;29(3):529-42.
DOI: 10.1007/s10555-010-9244-1
PMID: 20717705;
PMCID: PMC2933847.
 106. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. *Oncol Rep*. 2010 Sep;24(3):747-57.
DOI: 10.3892/or_00000917
PMID: 20664983.
 107. Sagar SM, Yance D, Wong RK. Natural health products that inhibit angiogenesis: A

- potential source for investigational new agents to treat cancer-Part 1. *Curr Oncol.* 2006 Feb;13(1):14-26.
 PMID: 17576437;
 PMCID: PMC1891166.
108. Sagar SM, Yance D, Wong RK. Natural health products that inhibit angiogenesis: A potential source for investigational new agents to treat cancer-Part 2. *Curr Oncol.* 2006 Jun;13(3):99-107.
 PMID: 17576449;
 PMCID: PMC1891180.
109. Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. Anticancer efficacy of polyphenols and their combinations nutrients. 2016 Sep 9;8(9):552.
 DOI: 10.3390/nu8090552
 PMID: 27618095;
 PMCID: PMC5037537.
110. Metwally AA, El-Ahmady SH, Hathout RM. Selecting optimum protein nano-carriers for natural polyphenols using chemoinformatics tools. *Phytomedicine.* 2016 Dec 15;23(14):1764-1770.
 DOI: 10.1016/j.phymed.2016.10.020
 Epub 2016 Oct 28.
 PMID: 27912878.
111. Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, Bahramsoltani R, Karimi-Soureh Z, Rahimi R, Abdollahi M. Polyphenol nanoformulations for cancer therapy: Experimental evidence and clinical perspective. *International Journal of Nanomedicine.* 2017;12:2689–2702.
 Available:<https://doi.org/10.2147/IJN.S131973>
 PMID: 28435252.
112. Available:<https://www.ncbi.nlm.nih.gov/pmc/?term=epigenetic+toxins+and+human+cancers>
113. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. *Curr Opin Pediatr.* 2009 Apr;21(2):243-51.
 DOI: 10.1097/mop.0b013e32832925cc
 PMID: 19663042;
 PMCID: PMC3035853.
114. Kim M, Bae M, Na H, Yang M. Environmental toxicants--induced epigenetic alterations and their reversers. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.* 2012;30(4):323-67.
 DOI: 10.1080/10590501.2012.731959.
 Erratum in: *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.* 2013;31(3):285.
 PMID: 23167630.
115. Cai FF, Kohler C, Zhang B, Wang MH, Chen WJ, Zhong XY. Epigenetic therapy for breast cancer. *Int J Mol Sci.* 2011;12(7):4465-87.
 DOI: 10.3390/ijms12074465
 Epub 2011 Jul 11.
 PMID: 21845090;
 PMCID: PMC3155363.
116. Oh S, Ko JY, Oh C, Yoo KH. Targeting the epigenome as a novel therapeutic approach for breast cancer. *Adv Exp Med Biol.* 2017;1026:287-313.
 DOI: 10.1007/978-981-10-6020-5_14
 PMID: 29282690.
117. Falahi F, van Kruchten M, Martinet N, Hospers GA, Rots MG. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. *Breast Cancer Res.* 2014 Jul 29;16(4):412.
 DOI: 10.1186/s13058-014-0412-z
 PMID: 25410383;
 PMCID: PMC4303227.
118. Hillyar C, Rallis KS, Varghese J. Advances in epigenetic cancer therapeutics. *Cureus.* 2020 Nov 27;12(11):e11725.
 DOI: 10.7759/cureus.11725
 PMID: 33391954;
 PMCID: PMC7772155.
119. Tsai HC, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. *Cancer Cell.* 2012 Mar 20;21(3):430-46.
 DOI: 10.1016/j.ccr.2011.12.029
 PMID: 22439938;
 PMCID: PMC3312044.
120. Tao Y, Liu S, Briones V, Geiman TM, Muegge K. Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS. *Nucleic Acids Res.* 2011 Dec;39(22):9508-20.
 DOI: 10.1093/nar/gkr611
 Epub 2011 Aug 31.
 PMID: 21880597;
 PMCID: PMC3239205.
121. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood.* 2004 Mar 1;103(5):1635-40.
 DOI: 10.1182/blood-2003-03-0687
 Epub 2003 Nov 6.

- PMID: 14604977.
122. Chen ZP, Schell JB, Ho CT, Chen KY. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. *Cancer Lett.* 1998 Jul 17;129(2):173-9.
DOI: 10.1016/s0304-3835(98)00108-6
PMID: 9719459
 123. Morr  DJ, Morr  DM. Synergistic Capsicum-tea mixtures with anticancer activity. *J Pharm Pharmacol.* 2003 Jul;55(7):987-94.
DOI: 10.1211/0022357021521
PMID: 12906756.
 124. Chueh PJ, Wu LY, Morr  DM, Morr  DJ. tNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (-)-epigallocatechin-3-gallate. *Biofactors.* 2004;20(4):235-49.
PMID: 15706060.
 125. Chang CF, Islam A, Liu PF, Zhan JH, Chueh PJ. Capsaicin acts through tNOX (ENOX2) to induce autophagic apoptosis in p53-mutated HSC-3 cells but autophagy in p53-functional SAS oral cancer cells. *Am J Cancer Res.* 2020 Oct 1;10(10):3230-3247.
PMID: 33163267;
PMCID: PMC7642647.
 126. Guais A, Baronzio G, Sanders E, Campion F, Mainini C, Fiorentini G, Montagnani F, Behzadi M, Schwartz L, Abolhassani M. Adding a combination of hydroxycitrate and lipoic acid (METABLOCTM) to chemotherapy improves effectiveness against tumor development: Experimental results and case report. *Invest New Drugs.* 2012 Feb;30(1):200-11.
DOI: 10.1007/s10637-010-9552-x
Epub 2010 Oct 8.
PMID: 20931262.
 127. Schwartz L, Abolhassani M, Guais A, Sanders E, Steyaert JM, Campion F, Isra l M. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: Preliminary results. *Oncol Rep.* 2010 May;23(5):1407-16.
DOI: 10.3892/or_00000778
PMID: 20372858.
 128. Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Metabolic treatment of cancer: Intermediate results of a prospective case series. *Anticancer Res.* 2014 Feb;34(2):973-80.
PMID: 24511042.
 129. Guais A, Baronzio G, Sanders E, Campion F, Mainini C, Fiorentini G, Montagnani F, Behzadi M, Schwartz L, Abolhassani M. Adding a combination of hydroxycitrate and lipoic acid (METABLOCTM) to chemotherapy improves effectiveness against tumor development: Experimental results and case report. *Invest New Drugs.* 2012 Feb;30(1):200-11.
DOI: 10.1007/s10637-010-9552-x
Epub 2010 Oct 8.
PMID: 20931262.
 130. Arima Y, Nobusue H, Saya H. Targeting of cancer stem cells by differentiation therapy. *Cancer Sci.* 2020 Aug;111(8):2689-2695.
DOI: 10.1111/cas.14504
Epub 2020 Jun 22.
PMID: 32462706;
PMCID: PMC7419023.
 131. Tun er S, Gurbanov R, Sheraj I, Solel E, Esenturk O, Banerjee S. Low dose dimethyl sulfoxide driven gross molecular changes have the potential to interfere with various cellular processes. *Scientific Reports.* 2018;8(1):14828.
Available:https://doi.org/10.1038/s41598-018-33234-z
PMID: 30287873.
 132. Fiore M, Zanier R, Degrassi F. Reversible G(1) arrest by dimethyl sulfoxide as a new method to synchronize Chinese hamster cells. *Mutagenesis.* 2002;17:419-424.
 133. Ossowski L, Belin D. Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin. *Molecular and Cellular Biology.* 1985;5(12):3552-3559.
Available:https://doi.org/10.1128/mcb.5.12.3552-3559.1985
PMID: 3837848.
 134. Breitman TR, He RY. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. *Cancer Res.* 1990 Oct 1;50(19):6268-73.
PMID: 2400989.
 135. Grunt TW, Somay C, Pavelka M, Ellinger A, Dittrich E, Dittrich C. The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells. *J Cell Sci.* 1991 Nov;100 (Pt 3):657-66.

- PMID: 1808213.
136. Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: A review of molecular mechanisms. *Biochem J.* 2012 Jan 1;441(1):61-76.
DOI: 10.1042/BJ20110744
PMID: 22168439;
PMCID: PMC4572477.
 137. Pandolfi F, Franza L, Mandolini C, Conti P. Immune modulation by Vitamin D: Special emphasis on its role in prevention and treatment of cancer. *Clin Ther.* 2017 May;39(5):884-893.
DOI: 10.1016/j.clinthera.2017.03.012
Epub 2017 Apr 18.
PMID: 28431765.
 138. Chatterjee M. Vitamin D and genomic stability. *Mutat Res.* 2001 Apr 18;475(1-2):69-87.
DOI: 10.1016/s0027-5107(01)00080-x
PMID: 11295155.
 139. Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. *Front Endocrinol (Lausanne).* 2012 Apr 23;3:58.
DOI: 10.3389/fendo.2012.00058
PMID: 22649423;
PMCID: PMC3355893.
 140. Bikle DD. Vitamin D and cancer: The promise not yet fulfilled. *Endocrine.* 2014 May;46(1):29-38.
DOI: 10.1007/s12020-013-0146-1
Epub 2014 Jan 9.
PMID: 24402695;
PMCID: PMC3976762.
 141. Thomson CA, Ho E, Strom MB. Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: Evidence from experimental and human studies. *Nutr Rev.* 2016 Jul;74(7):432-43.
DOI: 10.1093/nutrit/nuw010
Epub 2016 May 31.
PMID: 27261275;
PMCID: PMC5059820.
 142. Safe S, Papineni S, Chintharlapalli S. Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. *Cancer Lett.* 2008 Oct 8;269(2):326-38.
DOI: 10.1016/j.canlet.2008.04.021
Epub 2008 May 22.
PMID: 18501502;
PMCID: PMC2574232.
 143. Weng JR, Tsai CH, Kulp SK, Chen CS. Indole-3-carbinol as a chemopreventive and anti-cancer agent. *Cancer Lett.* 2008 Apr 18;262(2):153-63.
DOI: 10.1016/j.canlet.2008.01.033
Epub 2008 Mar 7.
PMID: 18314259;
PMCID: PMC2814317.
 144. Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. *Mol Cancer Ther.* 2007 Oct;6(10):2757-65.
DOI: 10.1158/1535-7163.MCT-07-0336
Epub 2007 Oct 3.
PMID: 17913854.
 145. Palomera-Sanchez Z, Watson GW, Wong CP, Beaver LM, Williams DE, Dashwood RH, Ho E. The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells. *J Nutr Biochem.* 2017 Sep;47:113-119.
DOI: 10.1016/j.jnutbio.2017.05.005
Epub 2017 May 25.
PMID: 28582660;
PMCID: PMC5583029.
 146. Watson WG, Beaver ML, Williams ED, Dashwood HR, Ho E. Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention. *AAPS J.* 2013 Oct;15(4):951-61.
DOI: 10.1208/s12248-013-9504-4
Epub 2013 Jun 26.
PMID: 23800833;
PMCID: PMC3787240.
 147. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? *AAPS J.* 2009 Sep;11(3):495-510.
DOI: 10.1208/s12248-009-9128-x
Epub 2009 Jul 10.
PMID: 19590964;
PMCID: PMC2758121.
 148. Park W, Amin AR, Chen ZG, Shin DM. New perspectives of curcumin in cancer prevention. *Cancer Prev Res (Phila).* 2013 May;6(5):387-400.
DOI: 10.1158/1940-6207.CAPR-12-0410
Epub 2013 Mar 6.
Erratum in: *Cancer Prev Res (Phila).* 2017 Jun;10(6):371.
PMID: 23466484;
PMCID: PMC3693758.
 149. Ji Z. Targeting DNA damage and repair by curcumin. *Breast Cancer (Auckl).* 2010 Feb 16;4:1-3.
PMID: 20697527;

- PMCID: PMC2914279.
150. Tortorella SM, Royce SG, Licciardi PV, Karagiannis TC. Dietary Sulforaphane in cancer chemoprevention: The role of epigenetic regulation and HDAC inhibition. *Antioxid Redox Signal.* 2015 Jun 1;22(16):1382-424.
DOI: 10.1089/ars.2014.6097
Epub 2014 Dec 19.
PMID: 25364882;
PMCID: PMC4432495.
 151. Clarke JD, Hsu A, Yu Z, Dashwood RH, Ho E. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. *Mol Nutr Food Res.* 2011 Jul;55(7):999-1009.
DOI: 10.1002/mnfr.201000547
Epub 2011 Mar 4.
PMID: 21374800;
PMCID: PMC3129466.
 152. Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane. *Cancer Lett.* 2008 Oct 8;269(2):291-304.
DOI: 10.1016/j.canlet.2008.04.018
Epub 2008 May 27.
PMID: 18504070;
PMCID: PMC2579766.
 153. Cho SD, Li G, Hu H, Jiang C, Kang KS, Lee YS, Kim SH, Lu J. Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. *Nutr Cancer.* 2005;52(2):213-24.
DOI: 10.1207/s15327914nc5202_11
PMID: 16201852.
 154. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. *Cancer Lett.* 2008 Oct 8;269(2):363-77.
DOI: 10.1016/j.canlet.2008.03.044
Epub 2008 May 13.
PMID: 18479809;
PMCID: PMC2572135.
 155. Jiang Y, Djuric Z, Sen A, Ren J, Kuklev D, Waters I, Zhao L, Uhlsou CL, Hong YH, Murphy RC, Normolle DP, Smith WL, Brenner DE. Biomarkers for personalizing omega-3 fatty acid dosing. *Cancer Prev Res (Phila).* 2014 Oct;7(10):1011-22.
DOI: 10.1158/1940-6207.CAPR-14-0134
Epub 2014 Aug 19.
PMID: 25139294;
PMCID: PMC4185239.
 156. Fabian CJ, Kimler BF, Phillips TA, Nydegger JL, Kreutzjans AL, Carlson SE, Hidaka BH, Metheny T, Zalles CM, Mills GB, Powers KR, Sullivan DK, Petroff BK, Hensing WL, Fridley BL, Hursting SD. Modulation of breast cancer risk biomarkers by high-dose Omega-3 fatty acids: Phase II pilot study in postmenopausal women. *Cancer Prev Res (Phila).* 2015 Oct;8(10):922-31.
DOI: 10.1158/1940-6207.CAPR-14-0336
Epub 2015 Aug 14.
PMID: 26276744;
PMCID: PMC4596784.
 157. Khadge S, Thiele GM, Sharp JG, McGuire TR, Klassen LW, Black PN, DiRusso CC, Talmadge JE. Long-Chain Omega-3 polyunsaturated fatty acids modulate mammary gland composition and inflammation. *J Mammary Gland Biol Neoplasia.* 2018 Jun;23(1-2):43-58.
DOI: 10.1007/s10911-018-9391-5
Epub 2018 Mar 25.
PMID: 29574638.
 158. McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: The potential of miRNA for diagnosis and treatment monitoring. *Cancer Metastasis Rev.* 2015 Mar;34(1):145-55.
DOI: 10.1007/s10555-015-9551-7
PMID: 25721950;
PMCID: PMC4368851.
 159. Hardman WE. Omega-3 fatty acids to augment cancer therapy. *J Nutr.* 2002 Nov;132(11 Suppl):3508S-3512S.
DOI: 10.1093/jn/132.11.3508S.
PMID: 12421878.
 160. Available:<https://medlineplus.gov/genetics/understanding/precisionmedicine/definition/>
 161. Willis RE. Targeted cancer therapy: Vital oncogenes and a new molecular genetic paradigm for cancer initiation progression and treatment. *Int J Mol Sci.* 2016 Sep 14;17(9):1552.
DOI: 10.3390/ijms17091552
PMID: 27649156;
PMCID: PMC5037825.
 162. Bielski CM, Taylor BS. Homing in on genomic instability as a therapeutic target in cancer. *Nat Commun.* 2021 Jun 16;12(1):3663.
DOI: 10.1038/s41467-021-23965-5
PMID: 34135330;
PMCID: PMC8209011.

163. Available: <https://www.carislifesciences.com/our-technology/>
164. Available: <https://www.foundationmedicine.com/test/foundationone-liquid-cdx>
165. Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, da Veiga Leprevost F, Jaehnig EJ, Lei JT, Wen B, Schnaubelt M. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. *Cancer cell*. 2021 Mar 8;39(3):361-79.
166. Available: <https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet>
167. Guide Treatment decisions in the first-line with Guardant360, REC-MKT-000039 R7.
168. Advani D, Sharma S, Kumari S, Ambasta RK, Kumar P. Precision oncology, signaling and anticancer agents in cancer therapeutics. *Anticancer Gents Med Chem*. 2021 Mar 7.
DOI: 10.2174/1871520621666210308101029
Epub ahead of print.
PMID: 33687887.
169. Ho W. Naturally occurring small molecules for disease and cancer treatment. World Scientific, Hackensack, N.J., U.S.A.; 2019. ISBN: 9789814525626
170. Somasundaram S. Natural products interactions on genomes. CRC Press, Boca Raton, FL, U.S.A.; 2016. ISBN-13 978-1-4398-7231-4
171. Sharif T, Alhosin M, Auger C, Minker C, Kim JH, Etienne-Selloum N, Bories P, Gronemeyer H, Lobstein A, Bronner C, Fuhrmann G, Schini-Kerth VB. *Aronia melanocarpa* juice induces a redox-sensitive p73-related caspase 3-dependent apoptosis in human leukemia cells. *PLoS One*. 2012;7(3):e32526.
DOI: 10.1371/journal.pone.0032526
Epub 2012 Mar 8.
PMID: 22412883;
PMCID: PMC3297612.
172. Sharif T, et al. The polyphenolic-rich *Aronia melanocarpa* juice kills teratocarcinoma cancer stem-like cells, but not their differentiated counterparts. *Journal of Functional Foods*. July 2013;5(3):1244-1252.
173. Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, Berry D, Steward W, Dennison A. The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. *Eur J Cancer*. 2009 Aug;45(12):2077-86.
DOI: 10.1016/j.ejca.2009.04.026
Epub 2009 Jun 1.
PMID: 19493674.
174. Kowshik J, Baba AB, Giri H, Deepak Reddy G, Dixit M, Nagini S. Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. *PLoS One*. 2014 Oct 8;9(10):e109114.
DOI: 10.1371/journal.pone.0109114
PMID: 25296162;
PMCID: PMC4189964.
175. Kowshik J, Nivetha R, Ranjani S, Venkatesan P, Selvamuthukumar S, Veeravarmal V, Nagini S. Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF- κ B/STAT3 signalling axis in oral squamous cell carcinoma models. *IUBMB Life*. 2019 Oct;71(10):1595-1610.
DOI: 10.1002/iub.2104
Epub 2019 Jun 28.
PMID: 31251469.
176. Fan J, Wu M, Wang J, Ren D, Zhao J, Yang G. 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one induces lung cancer cell apoptosis via the PI3K/Akt and ERK1/2 pathways. *J Cell Physiol*. 2019;234:6336-6349.
DOI: 10.1002/jcp.27364
PMID: 30246250.
177. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF- κ B activation. *FEBS Lett*. 2003 Sep 25;552(2-3):141-4.
DOI: 10.1016/s0014-5793(03)00905-0
PMID: 14527676.
178. Kim JH, Shim JS, Lee SK, Kim KW, Rha SY, Chung HC, Kwon HJ. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: Crucial involvement of the down-regulation of matrix metalloproteinase. *Jpn J Cancer Res*. 2002 Dec;93(12):1378-85.
DOI: 10.1111/j.1349-7006.2002.tb01247.x
PMID: 12495478;
PMCID: PMC5926931.
179. Huynh H, Nguyen TT, Chan E, Tran E. Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF- α)- and epidermal growth factor (EGF)-induced human PC-3

- prostate cancer cell proliferation. *Int J Oncol.* 2003 Sep;23(3):821-9.
PMID: 12888923.
180. Jiang C, Agarwal R, Lü J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. *Biochem Biophys Res Commun.* 2000 Sep 16;276(1):371-8.
DOI: 10.1006/bbrc.2000.3474
PMID: 11006131.
 181. Tang FY, Nguyen N, Meydani M. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. *Int J Cancer.* 2003 Oct 10;106(6):871-8.
DOI: 10.1002/ijc.11325
PMID: 12918064.
 182. Ahuja A, Kim JH, Kim JH, Yi YS, Cho JY. Functional role of ginseng-derived compounds in cancer. *J Ginseng Res.* 2018 Jul;42(3):248-254.
DOI: 10.1016/j.jgr.2017.04.009
Epub 2017 May 15.
PMID: 29983605;
PMCID: PMC6026353.
 183. Wang ZY, Nixon DW. Licorice and cancer. *Nutr Cancer.* 2001;39(1):1-11.
DOI: 10.1207/S15327914nc391_1
PMID: 11588889.
 184. Powell CB, Fung P, Jackson J, Dall'Era J, Lewkowicz D, Cohen I, Smith-McCune K. Aqueous extract of herba *Scutellaria barbatae*, a chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines. *Gynecol Oncol.* 2003 Nov;91(2):332-40.
DOI: 10.1016/j.ygyno.2003.07.004
PMID: 14599863.
 185. Alessandro Palmioli, et al. Natural compounds in cancer prevention: Effects of coffee extracts and their main polyphenolic component, 5-O-Caffeoylquinic acid, on oncogenic ras proteins. *Chem Asian J.* 2017 Sep 19;12(18):2457-2466.
PMID: 28719146.
 186. Fofaria NM, Ramachandran S, Srivastava SK. Therapeutic potential of black pepper compound for BRaf resistant melanoma. Presented at the 2nd International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 8–11 November 2017.
 187. Riedel, Stefan. Edward Jenner and the history of smallpox and vaccination. *Proceedings (Baylor University. Medical Center).* Baylor University Medical Center. January 2005;18(1):21–25.
DOI: 10.1080/08998280.2005.11928028
PMC: 1200696.
PMID:16200144.
 188. Baxby, Derrick. Jenner, Edward (1749–1823). *Oxford Dictionary of National Biography.* Oxford University Press.
 189. George Pearson, ed., *An Inquiry Concerning the History of the Cowpox, Principally with a View to Supersede and Extinguish the Smallpox* (London, England: J. Johnson, 1798);102–104.
 190. Thurston L, Williams G. An examination of John Fewster's role in the discovery of smallpox vaccination. *J R Coll Physicians Edinb.* 2015;45(2):173-9.
DOI: 10.4997/JRCPE.2015.217
PMID: 26181536.
 191. Plett PC. Peter Plett und die übrigen Entdecker der Kuhpockenimpfung vor Edward Jenner [Peter Plett and other discoverers of cowpox vaccination before Edward Jenner]. *Sudhoffs Arch.* 2006;90(2):219-32. German.
PMID: 17338405.
 192. History – Edward Jenner (1749–1823). BBC. 1 November 2006.
 193. Available:<https://www.cancer.gov/publications/dictionaries/cancer-terms/def/abscopal-effect>
 194. MOLE RH. Whole body irradiation; radiobiology or medicine? *Br J Radiol.* 1953 May;26(305):234-41.
DOI: 10.1259/0007-1285-26-305-234
PMID: 13042090.
 195. Demaria S, Formenti SC. The abscopal effect 67 years later: from a side story to center stage. *Br J Radiol.* 2020 May 1;93(1109):20200042.
DOI: 10.1259/bjr.20200042
Epub 2020 Feb 28.
PMID: 32101479;
PMCID: PMC7217574.
 196. Hodi FS, Dranoff G. The biologic importance of tumor-infiltrating lymphocytes. *J Cutan Pathol.* 2010 Apr;37 Suppl 1(01):48-53.
DOI: 10.1111/j.1600-0560.2010.01506.x
PMID: 20482675;
PMCID: PMC3905324.

197. Abdo J, Cornell DL, Mittal SK, Agrawal DK. Immunotherapy plus cryotherapy: Potential augmented abscopal effect for advanced cancers. *Front Oncol*. 2018 Mar 28;8:85. DOI: 10.3389/fonc.2018.00085 PMID: 29644213; PMCID: PMC5882833.
198. Yang X, Guo Y, Guo Z, Si T, Xing W, Yu W, Wang Y. Cryoablation inhibition of distant untreated tumors (abscopal effect) is immune mediated. *Oncotarget*. 2018 Jan 18;10(41):4180-4191. DOI: 10.18632/oncotarget.24105 PMID: 31289616; PMCID: PMC6609244.
199. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. *Clin Cancer Res*. 2009 Sep 1;15(17):5379-88. DOI: 10.1158/1078-0432.CCR-09-0265 Epub 2009 Aug 25. PMID: 19706802; PMCID: PMC2746048.
200. Liu SZ. Cancer control related to stimulation of immunity by low-dose radiation. *Dose Response*. 2006 Aug 28;5(1):39-47. DOI: 10.2203/dose-response.06-108.Liu PMID: 18648611; PMCID: PMC2477702.
201. Liu SZ. Nonlinear dose-response relationship in the immune system following exposure to ionizing radiation: Mechanisms and implications. *Nonlinearity Biol Toxicol Med*. 2003 Jan;1(1):71-92. DOI: 10.1080/15401420390844483 PMID: 19330113; PMCID: PMC2651616.
202. Zhou L, Zhang X, Li H, Niu C, Yu D, Yang G, Liang X, Wen X, Li M, Cui J. Validating the pivotal role of the immune system in low-dose radiation-induced tumor inhibition in Lewis lung cancer-bearing mice. *Cancer Med*. 2018 Apr;7(4):1338-1348. DOI: 10.1002/cam4.1344 Epub 2018 Feb 25. PMID: 29479834; PMCID: PMC5911597.
203. Takahashi Y, Matsutani N, Nakayama T, Dejima H, Uehara H, Kawamura M. Immunological effect of local ablation combined with immunotherapy on solid malignancies. *Chin J Cancer*. 2017 Jun 7;36(1):49. DOI: 10.1186/s40880-017-0216-5 PMID: 28592286; PMCID: PMC5463413.
204. Mauri G, Nicosia L, Xu Z, Di Pietro S, Monfardini L, Bonomo G, Varano GM, Prada F, Della Vigna P, Orsi F. Focused ultrasound: Tumour ablation and its potential to enhance immunological therapy to cancer. *Br J Radiol*. 2018 Feb;91(1083):20170641. DOI: 10.1259/bjr.20170641 Epub 2018 Jan 17. PMID: 29168922; PMCID: PMC5965486.
205. Ko EC, Formenti SC. Radiotherapy and checkpoint inhibitors: A winning new combination? *Ther Adv Med Oncol*. 2018 Apr 11;10:1758835918768240. DOI: 10.1177/1758835918768240 PMID: 29662550; PMCID: PMC5898659.
206. Zhao X, Shao C. Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade. *Cancers (Basel)*. 2020 Sep 25;12(10):2762. DOI: 10.3390/cancers12102762 PMID: 32992835; PMCID: PMC7600068.
207. Stoff JA, Clinical onco-immunology: Immune reconstitution, A place to start. *Current Trends in Immunology*. 2020;21:1-15. ISSN: 0972-4567
208. Caris Life Sciences, Immunotherapy. Available:<https://www.carislifesciences.com/cmi-overview/immunotherapy/> Accessed: August 10, 2018
209. Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. *Cytokine*. 2017 Jan;89:127-135. DOI: 10.1016/j.cyto.2016.01.021 Epub 2016 Feb 4. PMID: 26854213.
210. Riddell SR. Progress in cancer vaccines by enhanced self-presentation. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(16):8933-8935.
211. Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. *Lancet Oncol*. 2017 Dec;18(12):e731-e741. DOI: 10.1016/S1470-2045(17)30607-1

- PMID: 29208439.
212. Tang XJ, Sun XY, Huang KM, Zhang L, Yang ZS, Zou DD, Wang B, Warnock GL, Dai LJ, Luo J. Therapeutic potential of CAR-T cell-derived exosomes: A cell-free modality for targeted cancer therapy. *Oncotarget*. 2015 Dec 29;6(42):44179-90. DOI: 10.18632/oncotarget.6175 PMID: 26496034; PMCID: PMC4792550.
 213. Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. *EMBO Mol Med*. 2017 Sep;9(9):1183-1197. DOI: 10.15252/emmm.201607485 PMID: 28765140; PMCID: PMC5582407.
 214. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. *Cancer Discov*. 2013 Apr;3(4):388-98. DOI: 10.1158/2159-8290.CD-12-0548 Epub 2013 Apr 2. PMID: 23550147; PMCID: PMC3667586.
 215. Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts. *Trends Immunol*. 2015 Aug;36(8):494-502. DOI: 10.1016/j.it.2015.06.004 Epub 2015 Jul 11. PMID: 26169254; PMCID: PMC4746114.
 216. Hu ZI, McArthur HL, Ho AY. The abscopal effect of radiation therapy: What is it and how can we use it in breast cancer? *Curr Breast Cancer Rep*. 2017;9(1):45-51. DOI: 10.1007/s12609-017-0234-y Epub 2017 Mar 2. PMID: 28344743; PMCID: PMC5346418.
 217. Reynders K, Illidge T, Siva S, Chang JY, De Ruyscher D. The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant. *Cancer Treat Rev*. 2015 Jun;41(6):503-10. DOI: 10.1016/j.ctrv.2015.03.011 Epub 2015 Mar 28. PMID: 25872878; PMCID: PMC4816218.
 218. Chicas-Sett R, Morales-Orue I, Rodriguez-Abreu D, Lara-Jimenez P. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. *Clin Transl Radiat Oncol*. 2017 Dec 23;9:5-11. DOI: 10.1016/j.ctro.2017.12.004 PMID: 29594244; PMCID: PMC5862682.
 219. Stoff J, Clouatre J. *The prostate miracle*. New York: Kensington Publishing Corp., 2000:199;Chapter 7. ISBN: 1-57566-544-1
 220. Nemoto T, Han T, Minowada J, Angkur V, Chamberlain A, Dao L. Cell-mediated immune status of breast cancer patients: Evaluation by skin tests, lymphocyte stimulation, and counts of rosette-forming cells. *J Natl Cancer Inst*. 1974 Sep;53(3):641-5. PMID: 4606319.
 221. Kniker WT, Lesourd BM, McBryde JL, Corriel RN. Cell-mediated immunity assessed by Multitest CMI skin testing in infants and preschool children. *Am J Dis Child*. 1985;139(8):840-845. DOI:10.1001/archpedi.1985.02140100102044
 222. Mertins SD. Cancer stem cells: A systems biology view of their role in prognosis and therapy. *Anticancer Drugs*. 2014 Apr;25(4):353-67. DOI: 10.1097/CAD.0000000000000075 PMID: 24418909; PMCID: PMC4010870.
 223. Qiu H, Fang X, Luo Q, Ouyang G. Cancer stem cells: A potential target for cancer therapy. *Cell Mol Life Sci*. 2015 Sep;72(18):3411-24. DOI: 10.1007/s00018-015-1920-4 Epub 2015 May 13. PMID: 25967289.
 224. Maitland NJ, Collins AT. Cancer stem cells - A therapeutic target? *Curr Opin Mol Ther*. 2010 Dec;12(6):662-73. PMID: 21154158.
 225. García-Rubiño ME, Lozano-López C, Campos JM. Inhibitors of cancer stem cells. *Anticancer Agents Med Chem*. 2016;16(10):1230-9. DOI: 10.2174/1871520616666160330104715 PMID: 27025655.
 226. Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: Are they ready for the clinic? *Eur J Cancer*. 2012 Sep;48(14):2104-16. DOI: 10.1016/j.ejca.2012.03.019 Epub 2012 Apr 26. PMID: 22542086.

227. Kharkar PS. Cancer stem cell (CSC) inhibitors: A review of recent patents (2012-2015). *Expert Opin Ther Pat.* 2017 Jul;27(7):753-761.
DOI: 10.1080/13543776.2017.1325465
Epub 2017 May 5.
PMID: 28460551.
228. Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: Therapeutic implications and challenges. *Acta Pharmacol Sin.* 2013 Jun;34(6):732-40.
DOI: 10.1038/aps.2013.27
Epub 2013 May 20.
PMID: 23685952;
PMCID: PMC3674516.
229. Hirsch HA, Iliopoulos D, Tsiachlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. *Cancer Res.* 2009 Oct 1;69(19):7507-11.
DOI: 10.1158/0008-5472.CAN-09-2994
Epub 2009 Sep 14.
Erratum in: *Cancer Res.* 2009 Nov 15;69(22):8832.
PMID: 19752085;
PMCID: PMC2756324.
230. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. *Proc Natl Acad Sci U S A.* 2013 Jan 15;110(3):972-7.
DOI: 10.1073/pnas.1221055110
Epub 2012 Dec 31.
PMID: 23277563;
PMCID: PMC3549132.
231. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: How intimate is this relationship. *Mol Cell Biochem.* 2010 Mar;336(1-2):25-37.
DOI: 10.1007/s11010-009-0267-2
Epub 2009 Oct 8.
PMID: 19823771;
PMCID: PMC3148942.
232. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. *Cancer Res.* 2011 May 1;71(9):3196-201.
DOI: 10.1158/0008-5472.CAN-10-3471
Epub 2011 Mar 17.
PMID: 21415163;
PMCID: PMC3085572.
233. Rosa R, D'Amato V, De Placido S, Bianco R. Approaches for targeting cancer stem cells drug resistance. *Expert Opin Drug Discov.* 2016 Dec;11(12):1201-1212.
DOI: 10.1080/17460441.2016.1243525
Epub 2016 Oct 14.
PMID: 27700193.
234. Dragu DL, Necula LG, Bleotu C, Diaconu CC, Chivu-Economescu M. Therapies targeting cancer stem cells: Current trends and future challenges. *World J Stem Cells.* 2015 Oct 26;7(9):1185-201.
DOI: 10.4252/wjsc.v7.i9.1185
PMID: 26516409;
PMCID: PMC4620424.
235. Kim YR, Yoo JK, Jeong CW, Choi JW. Selective killing of circulating tumor cells prevents metastasis and extends survival. *J Hematol Oncol.* 2018 Sep 10;11(1):114.
DOI: 10.1186/s13045-018-0658-5
Erratum in: *J Hematol Oncol.* 2019 Jan 9;12(1):5.
PMID: 30201021;
PMCID: PMC6131899.
236. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell.* 2011 Mar 4;144(5):646-74.
DOI: 10.1016/j.cell.2011.02.013
PMID: 21376230.
237. Curtarelli RB, Gonçalves JM, Dos Santos LGP, Savi MG, Nör JE, Mezzomo LAM, Rodríguez Cordeiro MM. Expression of cancer stem cell biomarkers in human head and neck carcinomas: A systematic review. *Stem Cell Rev Rep.* 2018 Dec;14(6):769-784.
DOI: 10.1007/s12015-018-9839-4
PMID: 30076557.
238. Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S, Kossatz-Boehlert U. Cancer stem cells-origins and biomarkers: Perspectives for targeted personalized therapies. *Front Immunol.* 2020 Aug 7;11:1280.
DOI: 10.3389/fimmu.2020.01280
PMID: 32849491;
PMCID: PMC7426526.
239. Guo R, Chu A, Gong Y. Identification of cancer stem cell-related biomarkers in intestinal-type and diffuse-type gastric cancer by stemness index and weighted correlation network analysis. *J Transl Med.* 2020 Nov 7;18(1):418.
DOI: 10.1186/s12967-020-02587-3
PMID: 33160391;
PMCID: PMC7648412.

240. Zeng S, Shen WH, Liu L. Senescence and Cancer. *Cancer Transl Med.* 2018 May-Jun;4(3):70-74.
DOI: 10.4103/ctm.ctm_22_18
Epub 2018 Jun 29.
PMID: 30766922;
PMCID: PMC6372122.
241. Basu AK. DNA Damage, mutagenesis and cancer. *Int J Mol Sci.* 2018 Mar 23;19(4):970.
DOI: 10.3390/ijms19040970
PMID: 29570697;
PMCID: PMC5979367.
242. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. *Nature.* 2001 Nov 1;414(6859):105-11.
DOI: 10.1038/35102167
PMID: 11689955
243. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. *Int J Biochem Cell Biol.* 2012 Dec;44(12):2144-51.
DOI: 10.1016/j.biocel.2012.08.022
Epub 2012 Sep 2.
PMID: 22981632;
PMCID: PMC3496019.
244. Osman A, Afify SM, Hassan G, Fu X, Seno A, Seno M. Revisiting cancer stem cells as the origin of cancer-associated cells in the tumor microenvironment: A hypothetical view from the potential of iPSCs. *Cancers (Basel).* 2020 Apr 4;12(4):879.
DOI: 10.3390/cancers12040879
PMID: 32260363;
PMCID: PMC7226406.
245. Forster T, Rausch V, Zhang Y, Isayev O, Heilmann K, Schoensiegel F, Liu L, Nessling M, Richter K, Labsch S, Nwaeburu CC, Mattern J, Gladkich J, Giese N, Werner J, Schemmer P, Gross W, Gebhard MM, Gerhauser C, Schaefer M, Herr I. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. *Oncotarget.* 2014 Mar 30;5(6):1621-34.
DOI: 10.18632/oncotarget.1764
PMID: 24742583;
PMCID: PMC4039235.
246. Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, Yu Y, Clouthier SG, Schwartz SJ, Wicha MS, Sun D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. *Clin Cancer Res.* 2010 May 1;16(9):2580-90.
DOI: 10.1158/1078-0432.CCR-09-2937
Epub 2010 Apr 13.
PMID: 20388854;
PMCID: PMC2862133.
247. Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling perturbation by natural products. *Cell Signal.* 2009 Nov;21(11):1541-7.
DOI: 10.1016/j.cellsig.2009.03.009
Epub 2009 Mar 16.
PMID: 19298854;
PMCID: PMC2756420.
248. Jin H, Gong W, Zhang C, Wang S. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. *Onco Targets Ther.* 2013;6:145-53.
DOI: 10.2147/OTT.S40914
Epub 2013 Mar 8.
PMID: 23525843;
PMCID: PMC3596123.
249. Ogawa K, Hara T, Shimizu M, Nagano J, Ohno T, Hoshi M, Ito H, Tsurumi H, Saito K, Seishima M, Moriwaki H. (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. *Oncol Lett.* 2012 Sep;4(3):546-550.
DOI: 10.3892/ol.2012.761
Epub 2012 Jun 15.
PMID: 23741252;
PMCID: PMC3673646.
250. Moselhy J, Srinivasan S, Ankem MK, Damodaran C. Natural products that target cancer stem cells. *Anticancer Res.* 2015 Nov;35(11):5773-88.
PMID: 26503998;
PMCID: PMC7523548.
251. Weaver BA. How Taxol/paclitaxel kills cancer cells. *Mol Biol Cell.* 2014 Sep 15;25(18):2677-81.
DOI: 10.1091/mbc.E14-04-0916
PMID: 25213191;
PMCID: PMC4161504.
252. Moudi M, Go R, Yien CY, Nazre M. Vinca alkaloids. *Int J Prev Med.* 2013 Nov;4(11):1231-5.
PMID: 24404355;
PMCID: PMC3883245.
253. Saini N, Yang X. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. *Acta Biochim Biophys Sin (Shanghai).* 2018 Feb 1;50(2):133-143.
DOI: 10.1093/abbs/gmx106
PMID: 29342230.
254. Kim TH, Suh DH, Kim MK, Song YS. Metformin against cancer stem cells through the modulation of energy

- metabolism: Special considerations on ovarian cancer. *Biomed Res Int.* 2014;2014:132702.
DOI: 10.1155/2014/132702
Epub 2014 Jun 24.
PMID: 25050322;
PMCID: PMC4094711.
255. Zhao B, Luo J, Wang Y, Zhou L, Che J, Wang F, Peng S, Zhang G, Shang P. Metformin suppresses self-renewal ability and tumorigenicity of osteosarcoma stem cells via reactive oxygen species-mediated apoptosis and autophagy. *Oxid Med Cell Longev.* 2019 Nov 18;2019:9290728.
DOI: 10.1155/2019/9290728
PMID: 31827709;
PMCID: PMC6885828.
256. Daugan M, Dufajř Wojcicki A, d'Hayer B, Boudy V. Metformin: An anti-diabetic drug to fight cancer. *Pharmacol Res.* 2016 Nov;113(Pt A):675-685.
DOI: 10.1016/j.phrs.2016.10.006
Epub 2016 Oct 5.
PMID: 27720766.
257. Rico M, Baglioni M, Bondarenko M, Laluce NC, Rozados V, André N, Carré M, Scharovsky OG, Menacho Márquez M. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. *Oncotarget.* 2017 Jan 10;8(2):2874-2889.
DOI: 10.18632/oncotarget.13760
PMID: 27926515;
PMCID: PMC5356849.
258. Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, Gregato G, Labanca V, Rossi T, Noonan DM, Albini A, Bertolini F. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. *Sci Rep.* 2016 Jan 5;6:18673.
DOI: 10.1038/srep18673
PMID: 26728433;
PMCID: PMC4700497.
259. Available: <https://www.anticancerfund.org/en/redo-db>
Accessed 9/4/21
260. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. *Oncotarget.* 2015 Mar 10;6(7):4569-84.
DOI: 10.18632/oncotarget.3174
PMID: 25625193;
PMCID: PMC4467100.
261. Sotgia F, Ozsvari B, Fiorillo M, De Francesco EM, Bonuccelli G, Lisanti MP. A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. *Cell Cycle.* 2018;17(17):2091-2100.
DOI: 10.1080/15384101.2018.1515551
Epub 2018 Sep 26.
PMID: 30257595;
PMCID: PMC6226227.
262. Qiao X, Wang X, Shang Y, Li Y, Chen SZ. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo. *Cancer Commun (Lond).* 2018 Jul 3;38(1):43.
DOI: 10.1186/s40880-018-0309-9
PMID: 29970185;
PMCID: PMC6029027.
263. Satheesh NJ, Samuel SM, Büsselberg D. Combination therapy with Vitamin C could eradicate cancer stem cells. *Biomolecules.* 2020 Jan 3;10(1):79.
DOI: 10.3390/biom10010079
PMID: 31947879;
PMCID: PMC7022456.
264. Fiorillo M, Tóth F, Sotgia F, Lisanti MP. Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). *Aging (Albany NY).* 2019 Apr 19;11(8):2202-2216.
DOI: 10.18632/aging.101905.
PMID: 31002656;
PMCID: PMC6520007.
265. Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. *PLoS One.* 2018 May 15;13(5):e0197422.
DOI: 10.1371/journal.pone.0197422
PMID: 29763460;
PMCID: PMC5953490.
266. Song S, Zhang Y, Ding T, Ji N, Zhao H. The dual role of Macropinocytosis in cancers: Promoting growth and inducing methuosis to participate in anticancer therapies as targets. *Front Oncol.* 2021 Jan 19;10:570108.
DOI: 10.3389/fonc.2020.570108
PMID: 33542897;
PMCID: PMC7851083.
267. Osaki M, Okada F. Exosomes and their role in cancer progression. *Yonago Acta Med.* 2019 Jun 20;62(2):182-190.

- DOI: 10.33160/yam.2019.06.002
 PMID: 31320822;
 PMCID: PMC6584259.
268. Yáñez-Mó M, et al. Biological properties of extracellular vesicles and their physiological functions. *J Extracell Vesicles*. 2015 May 14;4:27066.
 DOI: 10.3402/jev.v4.27066
 PMID: 25979354;
 PMCID: PMC4433489.
269. Katsuda T, Kosaka N, Ochiya T. The roles of extracellular vesicles in cancer biology: Toward the development of novel cancer biomarkers. *Proteomics*. 2014 Mar;14(4-5):412-25.
 DOI: 10.1002/pmic.201300389
 PMID: 24339442.
270. Taylor DD, Gerzel-Taylor C. Exosomes/microvesicles: Mediators of cancer-associated immunosuppressive microenvironments. *Semin Immunopathol*. 2011 Sep;33(5):441-54.
 DOI: 10.1007/s00281-010-0234-8
 Epub 2011 Jun 19.
 PMID: 21688197.
271. Seo N, Akiyoshi K, Shiku H. Exosome-mediated regulation of tumor immunology. *Cancer Sci*. 2018 Oct;109(10):2998-3004.
 DOI: 10.1111/cas.13735
 Epub 2018 Aug 1.
 PMID: 29999574;
 PMCID: PMC6172045.
272. Lugini L, Cecchetti S, Huber V, Luciani F, Macchia G, Spadaro F, Paris L, Abalsamo L, Colone M, Molinari A, Podo F, Rivoltini L, Ramoni C, Fais S. Immune surveillance properties of human NK cell-derived exosomes. *J Immunol*. 2012 Sep 15;189(6):2833-42.
 DOI: 10.4049/jimmunol.1101988
 Epub 2012 Aug 17.
 PMID: 22904309.
273. Nam GH, Choi Y, Kim GB, Kim S, Kim SA, Kim IS. Emerging Prospects of exosomes for cancer treatment: From conventional therapy to immunotherapy. *Adv Mater*. 2020 Dec;32(51):e2002440.
 DOI: 10.1002/adma.202002440
 Epub 2020 Oct 5.
 PMID: 33015883.
274. Lee NK, Kothandan VK, Kothandan S, Byun Y, Hwang SR. Exosomes and cancer stem cells in cancer immunity: Current reports and future directions. *Vaccines (Basel)*. 2021 May 1;9(5):441.
 DOI: 10.3390/vaccines9050441
 PMID: 34062950;
 PMCID: PMC8147426.
275. You B, Xu W, Zhang B. Engineering exosomes: A new direction for anticancer treatment. *Am J Cancer Res*. 2018 Aug 1;8(8):1332-1342.
 PMID: 30210908;
 PMCID: PMC6129493.
276. Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, Tao Y, He Z, Chen C, Jiang Y. Exosomes: Key players in cancer and potential therapeutic strategy. *Signal Transduct Target Ther*. 2020 Aug 5;5(1):145.
 DOI: 10.1038/s41392-020-00261-0
 PMID: 32759948;
 PMCID: PMC7406508.
277. Khwaja TA, Dias CB, Pentecost S. Recent studies on the anticancer activities of mistletoe (*Viscum album*) and its alkaloids. *Oncology*. 1986;43 Suppl 1:42-50.
 DOI: 10.1159/000226419
 PMID: 3543783.
278. Zarković N, Kalisnik T, Lončarić I, Borović S, Mang S, Kissel D, Konitzer M, Jurin M, Grainza S. Comparison of the effects of *Viscum album* lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10. *Cancer Biother Radiopharm*. 1998 Apr;13(2):121-31.
 DOI: 10.1089/cbr.1998.13.121
 PMID: 10850348.
279. Park JH, Hyun CK, Shin HK. Cytotoxic effects of the components in heat-treated mistletoe (*Viscum album*). *Cancer Lett*. 1999 May 24;139(2):207-13.
 DOI: 10.1016/s0304-3835(99)00043-9
 PMID: 10395180.
280. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: New rationale for new directions. *Nat Rev Clin Oncol*. 2010 Aug;7(8):455-65.
 DOI: 10.1038/nrclinonc.2010.82
 Epub 2010 Jun 8.
 PMID: 20531380.
281. Damyanov C, Gerasimova D, Maslev I, Gavrilov V. Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer. *ISRN Urol*. 2012;2012:140182.
 DOI: 10.5402/2012/140182
 Epub 2012 May 8.
 PMID: 22649741;
 PMCID: PMC3357525.

282. Jiao SC, Huang J, Sun Y, Lu SX. The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells. *Zhonghua Yi Xue Za Zhi*. 2003 Feb 10;83(3):195-7. Chinese. PMID: 12812659.
283. Lasalvia-Prisco E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Gordon W. Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. *Cancer Chemother Pharmacol*. 2004 Mar;53(3):220-4. DOI: 10.1007/s00280-003-0716-7 Epub 2003 Dec 4. PMID: 14655024.
284. DeVita VT Jr, Chu E. A history of cancer chemotherapy. *Cancer Res*. 2008 Nov 1;68(21):8643-53. DOI: 10.1158/0008-5472.CAN-07-6611 PMID: 18974103.
285. The Ayre Clinic for Contemporary Medicine, Development of IPT. Available:<http://contemporarymedicine.net/development-of-ipt/> Accessed 9/10/21
286. Agrawal S, Woźniak M, Łuc M, Makuch S, Pielka E, Agrawal AK, Wietrzyk J, Banach J, Gamian A, Pizon M, Ziółkowski P. Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2. *Sci Rep*. 2019 Nov 12;9(1):16647. DOI: 10.1038/s41598-019-53145-x PMID: 31719636; PMCID: PMC6851401.
287. Damyanov C, Radoslavova M, Gavrillov V, Stoeva D. Low dose chemotherapy in combination with insulin for the treatment of advanced metastatic tumors. Preliminary experience. *J BUON*. 2009 Oct-Dec;14(4):711-5. PMID: 20148468.
288. Ayre SG, Garcia y Bellon DP, Garcia DP Jr. Insulin, chemotherapy, and the mechanisms of malignancy: The design and the demise of cancer. *Med Hypotheses*. 2000 Oct;55(4):330-4. DOI: 10.1054/mehy.2000.1063 PMID: 11000062.
289. Available:<https://cam-cancer.org/en/insulin-potential-therapy>
290. Available:<https://contemporarymedicine.net/articles-and-publications/>
291. Available:<https://www.cancertherapyadvisor.com/home/cancer-treatment-regimens/>
292. Xie L, Zhao T, Cai J, Su Y, Wang Z, Dong W. Methotrexate induces DNA damage and inhibits homologous recombination repair in choriocarcinoma cells. *Oncotargets Ther*. 2016 Nov 17;9:7115-7122. DOI: 10.2147/OTT.S116387 PMID: 27895503; PMCID: PMC5119623.
293. Moon JW, Lee SK, Lee JO, Kim N, Lee YW, Kim SJ, Kang HJ, Kim J, Kim HS, Park SH. Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer. *J Exp Clin Cancer Res*. 2014 Jan 6;33(1):4. DOI: 10.1186/1756-9966-33-4 PMID: 24393480; PMCID: PMC3923411.
294. Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B, Cheng SY. Stem cell programs in cancer initiation, progression, and therapy resistance. *Theranostics*. 2020 Jul 9;10(19):8721-8743. DOI: 10.7150/thno.41648 PMID: 32754274; PMCID: PMC7392012.
295. Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: Complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. *Carcinogenesis*. 2013 Apr;34(4):725-38. DOI: 10.1093/carcin/bgt086 Epub 2013 Mar 1. PMID: 23455378; PMCID: PMC3616676.
296. Lai JI, Tseng YJ, Chen MH, Huang CF, Chang PM. Clinical perspective of FDA approved drugs with P-Glycoprotein inhibition activities for potential cancer therapeutics. *Front Oncol*. 2020 Nov 16;10:561936. DOI: 10.3389/fonc.2020.561936 PMID: 33312947; PMCID: PMC7704056.
297. Nanayakkara AK, Follit CA, Chen G, Williams NS, Vogel PD, Wise JG. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. *Sci Rep*. 2018 Jan 17;8(1):967. DOI: 10.1038/s41598-018-19325-x PMID: 29343829; PMCID: PMC5772368.
298. De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance. *Expert*

- Opin Pharmacother. 2005 Jun;6(7):1049-54.
DOI: 10.1517/14656566.6.7.1049
PMID: 15957961.
299. Chen M, Lu J, Wei W, Lv Y, Zhang X, Yao Y, Wang L, Ling T, Zou X. Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1 α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo. *Onco Targets Ther.* 2018 Oct 10;11:6705-6722.
DOI: 10.2147/OTT.S161198
PMID: 30349304;
PMCID: PMC6188003.
300. Kienle GS, Kiene H. Review article: Influence of *Viscum album* L (European mistletoe) extracts on quality of life in cancer patients: A systematic review of controlled clinical studies. *Integr Cancer Ther.* 2010 Jun;9(2):142-57.
DOI: 10.1177/1534735410369673
Epub 2010 May 18.
PMID: 20483874.
301. Bar-Sela G, Gershony A, Haim N. [Mistletoe (*Viscum album*) preparations: An optional drug for cancer patients?]. *Harefuah.* 2006 Jan;145(1):42-6, 77. Hebrew.
PMID: 16450726.
302. Ostermann T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): A systematic literature review. *BMC Cancer.* 2009 Dec 18;9:451.
DOI: 10.1186/1471-2407-9-451
PMID: 20021637;
PMCID: PMC2804713.
303. Gutsch J, Werthmann PG, Rosenwald A, Kienle GS. Complete remission and long-term survival of a patient with a diffuse large B-cell lymphoma under *Viscum album* extracts after resistance to R-CHOP: A case report. *Anticancer Res.* 2018 Sep;38(9):5363-5369.
DOI: 10.21873/anticancer.12865
PMID: 30194190.
304. Siegle I, Fritz P, McClellan M, Gutzeit S, Mürdter TE. Combined cytotoxic action of *Viscum album* agglutinin-1 and anticancer agents against human A549 lung cancer cells. *Anticancer Res.* 2001 Jul-Aug;21(4A):2687-91.
PMID: 11724340.
305. Weissenstein U, Kunz M, Urech K, Baumgartner S. Interaction of standardized mistletoe (*Viscum album*) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. *BMC Complement Altern Med.* 2014 Jan 8;14:6.
DOI: 10.1186/1472-6882-14-6
PMID: 24397864;
PMCID: PMC3893555.
306. Melo MNO, Oliveira AP, Wicikowski AF, Carvalho RS, Castro JL, de Oliveira FAG, Pereira HMG, da Veiga VF, Capella MMA, Rocha L, Holandino C. Phenolic compounds from *Viscum album* tinctures enhanced antitumor activity in melanoma murine cancer cells. *Saudi Pharm J.* 2018 Mar;26(3):311-322.
DOI: 10.1016/j.jsps.2018.01.011
Epub 2018 Jan 31.
PMID: 29556122;
PMCID: PMC5856955.
307. Menke K, Schwermer M, Schramm A, Zuzak TJ. Preclinical evaluation of antitumoral and cytotoxic properties of *Viscum album* Fraxini extract on pediatric tumor cells. *Planta Med.* 2019 Oct;85(14-15):1150-1159.
DOI: 10.1055/a-1013-0382
Epub 2019 Oct 7.
PMID: 31590196.
308. Klingbeil MF, Xavier FC, Sardinha LR, Severino P, Mathor MB, Rodrigues RV, Pinto DS Jr. Cytotoxic effects of mistletoe (*Viscum album* L.) in head and neck squamous cell carcinoma cell lines. *Oncol Rep.* 2013 Nov;30(5):2316-22.
DOI: 10.3892/or.2013.2732
Epub 2013 Sep 10.
PMID: 24026291.
309. Chen YY, Hou JP, Huang L, Khan A, Xing FF, Zhang XH, Han DF, Yan SL, Cao GD, Jiao QY, Liu D, Zhu X, Hu Q, Lou HX. Chemical constituents of *Viscum coloratum* (Kom.) Nakai and their cytotoxic activities. *Nat Prod Res.* 2020 Oct 27:1-7.
DOI: 10.1080/14786419.2020.1837816
Epub ahead of print.
PMID: 33107346.
310. Sabová L, Pilátová M, Szilagyi K, Sabo R, Mojzis J. Cytotoxic effect of mistletoe (*Viscum album* L.) extract on Jurkat cells and its interaction with doxorubicin. *Phytother Res.* 2010 Mar;24(3):365-8.
DOI: 10.1002/ptr.2947
PMID: 19610041.
311. Wu F, Li J, Jang C, Wang J, Xiong J. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small

- cell lung carcinoma. *Int J Clin Exp Pathol*. 2014 Sep 15;7(10):6653-61.
PMID: 25400744;
PMCID: PMC4230140.
312. Kim S, Kim KC, Lee C. Mistletoe (*Viscum album*) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells. *Phytomedicine*. 2017 Dec 1;36:183-193.
DOI: 10.1016/j.phymed.2017.09.017
Epub 2017 Sep 29.
PMID: 29157814.
313. Emmings E, Mullany S, Chang Z, Landen CN Jr, Linder S, Bazzaro M. Targeting mitochondria for treatment of chemoresistant ovarian cancer. *Int J Mol Sci*. 2019 Jan 8;20(1):229.
DOI: 10.3390/ijms20010229
PMID: 30626133;
PMCID: PMC6337358.
314. Lamb R, Fiorillo M, Chadwick A, Ozsvari B, Reeves KJ, Smith DL, Clarke RB, Howell SJ, Cappello AR, Martinez-Outschoorn UE, Peiris-Pagès M, Sotgia F, Lisanti MP. Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. *Oncotarget*. 2015 Jun 10;6(16):14005-25.
DOI: 10.18632/oncotarget.4159
PMID: 26087309;
PMCID: PMC4546447.
315. Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B, Cheng SY. Stem cell programs in cancer initiation, progression, and therapy resistance. *Theranostics*. 2020 Jul 9;10(19):8721-8743.
DOI: 10.7150/thno.41648
PMID: 32754274;
PMCID: PMC7392012.
316. Alisi A, Cho WC, Locatelli F, Fruci D. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. *Int J Mol Sci*. 2013 Dec 18;14(12):24706-25.
DOI: 10.3390/ijms141224706
PMID: 24351843;
PMCID: PMC3876137.
317. McIntosh K, Balch C, Tiwari AK. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells. *Expert Opin Drug Metab Toxicol*. 2016 Jun;12(6):633-44.
DOI: 10.1080/17425255.2016.1179280
Epub 2016 May 4.
PMID: 27116192.
318. Garcia-Mayea Y, Mir C, Masson F, Paciucci R, Leonart ME. Insights into new mechanisms and models of cancer stem cell multidrug resistance. *Semin Cancer Biol*. 2020 Feb;60:166-180.
DOI: 10.1016/j.semcancer.2019.07.022
Epub 2019 Jul 29.
PMID: 31369817.
319. Zhang Q, Feng Y, Kennedy D. Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this? *Cell Mol Life Sci*. 2017 Mar;74(5):777-801.
DOI: 10.1007/s00018-016-2362-3
Epub 2016 Sep 12.
PMID: 27622244.
320. Gilloteaux J, Jamison JM, Lorimer HE, Jarjoura D, Taper HS, Calderon PB, Neal DR, Summers JL. Autoschizis: A new form of cell death for human ovarian carcinoma cells following ascorbate: Menadione treatment. Nuclear and DNA degradation. *Tissue Cell*. 2004 Jun;36(3):197-209.
DOI: 10.1016/j.tice.2004.01.006
PMID: 15140597.
321. Jamison JM, Gilloteaux J, Taper HS, Calderon PB, Summers JL. Autoschizis: A novel cell death. *Biochem Pharmacol*. 2002 May 15;63(10):1773-83.
DOI: 10.1016/s0006-2952(02)00904-8
PMID: 12034362.
322. Verrax J, Cadrobbi J, Delvaux M, Jamison JM, Gilloteaux J, Summers JL, Taper HS, Buc Calderon P. The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. *Eur J Med Chem*. 2003 May;38(5):451-7.
DOI: 10.1016/s0223-5234(03)00082-5
PMID: 12767595.
323. Fu J, Wu Z, Liu J, Wu T. Vitamin C: A stem cell promoter in cancer metastasis and immunotherapy. *Biomed Pharmacother*. 2020 Nov;131:110588.
DOI: 10.1016/j.biopha.2020.110588
Epub 2020 Aug 21.
PMID: 32836076.
324. Satheesh NJ, Samuel SM, Büsselberg D. Combination Therapy with Vitamin C could eradicate cancer stem cells. *Biomolecules*. 2020 Jan 3;10(1):79.
DOI: 10.3390/biom10010079
PMID: 31947879;
PMCID: PMC7022456.

